<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2411222928
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INVEGA SUSTENNA 50 mg
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PALIPERIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        646.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN PHARMACEUTICA N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN-CILAG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Invega&reg; Sustenna &reg; contains the active substance paliperidone which belongs to the class of antipsychotic medicines and is used as a maintenance treatment for the symptoms of schizophrenia in adult patients stabilised on paliperidone or risperidone.<br />If you have shown responsiveness to paliperidone or risperidone in the past and have mild to moderate symptoms your doctor may start treatment with Invega&reg; Sustenna &reg; without prior stabilisation with paliperidone or risperidone.<br />Schizophrenia is a disease with &ldquo;positive&rdquo; and &ldquo;negative&rdquo; symptoms. Positive means an excess of symptoms that are not normally present. For example, a person with schizophrenia may hear voices or see things that are not there (called hallucinations), believe things that are not true (called delusions), or feel unusually suspicious of others. Negative means a lack of behaviours or feelings that are normally present. For example, a person with schizophrenia may appear withdrawn and may not respond at all emotionally or may have trouble speaking in a clear and logical way. People with this disease may also feel depressed, anxious, guilty, or tense.<br />Invega&reg; Sustenna &reg; can help alleviate the symptoms of your disease and stop your symptoms from coming back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Invega&reg; Sustenna &reg;</strong><br />- if you are allergic to paliperidone or to any of the other ingredients of this medicine (listed in section 6).<br />- if you are allergic to another antipsychotic medicine including the substance risperidone.<br /><br /><strong>Warnings and precautions</strong><br />Talk to your doctor, pharmacist or nurse before using Invega&reg; Sustenna &reg;.<br />This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia, who are treated with other similar types of medicine, may have an increased risk of stroke or death (see section 4, possible side effects).<br />All medicines have side effects and some of the side effects of this medicine can worsen the symptoms of other medical conditions. For that reason, it is important to discuss with your doctor any of the following conditions which can potentially worsen during treatment with this medicine:<br />- if you have Parkinson&rsquo;s disease<br />- if you have ever been diagnosed with a condition whose symptoms include high temperature and muscle stiffness (also known as Neuroleptic Malignant Syndrome)<br />- if you have ever experienced abnormal movements of the tongue or face (Tardive Dyskinesia)<br />- if you know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines)<br />- if you are diabetic or prone to diabetes<br />- if you have had breast cancer or a tumour in the pituitary gland in your brain<br />- if you have a heart disease or heart disease treatment that makes you prone to low blood pressure<br />- if you have low blood pressure when you stand up or sit up suddenly<br />- if you have epilepsy<br />- if you have kidney problems<br />- if you have liver problems<br />- if you have prolonged and/or painful erection<br />- if you have problems with controlling core body temperature or overheating<br />- if you have an abnormally high level of the hormone prolactin in your blood or if you have a possible prolactin-dependent tumour<br />- if you or someone else in your family has a history of blood clots, as antipsychotics have been associated with formation of blood clots.<br />If you have any of these conditions, please talk to your doctor as he/she may want to adjust your dose or monitor you for a while.<br />As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood has been seen very rarely with patients taking this medicine, your doctor may check your white blood cell counts.<br />Even if you have previously tolerated oral paliperidone or risperidone, rarely allergic reactions occur after receiving injections of Invega&reg; Sustenna &reg;. Seek medical attention right away if you experience a rash, swelling of your throat, itching, or problems breathing as these may be signs of a serious allergic reaction.<br />This medicine may cause you to gain weight. Significant weight gain may adversely affect your health. Your doctor should regularly measure your body weight.<br />As diabetes mellitus or worsening of pre-existing diabetes mellitus have been seen with patients taking this medicine, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus blood glucose should be monitored regularly.<br />Since this medicine may reduce your urge to vomit, there is a chance that it may mask the body&rsquo;s normal response to ingestion of toxic substances or other medical conditions.<br />During an operation on the eye for cloudiness of the lens (cataract), the pupil (the black circle in the middle of your eye) may not increase in size as needed. Also, the iris (the coloured part of the eye) may become floppy during surgery and that may lead to eye damage. If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine.<br /><br /><strong>Children and adolescents</strong><br />This medicine is not for people who are under 18 years old.<br />Other medicines and Invega&reg; Sustenna &reg;<br />Tell your doctor if you are taking, have recently taken or might take any other medicines.<br />Taking this medicine with carbamazepine (an anti-epileptic and mood stabiliser) may require a change to your dose of this medicine.<br />Since this medicine works primarily in the brain, interference from other medicines that work in the brain can cause an exaggeration of side effects such as sleepiness or other effects on the brain such as other psychiatric medications, opioids, antihistamines and sleep medication.<br />Since this medicine can lower blood pressure, care should be taken when this medicine is used with other medicines that lower blood pressure.<br />This medicine can reduce the effect of medicines against Parkinson&rsquo;s disease and restless legs syndrome (e.g., levodopa).<br />This medicine may cause an electrocardiogram (ECG) abnormality demonstrating a long time for an electrical impulse to travel through a certain part of the heart (known as &ldquo;QT prolongation&rdquo;). Other medicines that have this effect include some medicines used to treat the rhythm of the heart or to treat infection, and other antipsychotics.<br />If you are prone to develop convulsions, this medicine may increase your chance of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infection, and other antipsychotics.<br />Invega&reg; Sustenna &reg; should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).<br /><strong>Invega&reg; Sustenna &reg; with alcohol</strong><br />Alcohol should be avoided.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use this medicine during pregnancy unless this has been discussed with your doctor. The following symptoms may occur in newborn babies of mothers that have used paliperidone in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.<br />This medicine can pass from mother to baby through breast milk and may harm the baby. Therefore, you should not breastfeed when using this medicine.<br /><strong>Driving and using machines</strong><br />Dizziness, extreme tiredness and vision problems may occur during treatment with this medicine (see section 4). This should be considered in cases where full alertness is required, e.g., when driving a car or handling machines.<br /><strong>Invega&reg; Sustenna &reg; contains sodium</strong><br />This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is administered by your doctor or other healthcare professional. Your doctor will tell you when you need your next injection. It is important not to miss your scheduled dose. If you cannot keep your appointment with the doctor, make sure you call him right away so another appointment can be made as soon as possible.<br />You will receive the first injection (150 mg) and second injection (100 mg) of this medicine in the upper arm approximately one week apart. Thereafter, you will receive an injection (ranging from 25 mg to 150 mg) in either the upper arm or buttocks once a month.<br />If your doctor is switching you from risperidone long acting injection to this medicine, you will receive the first injection of this medicine (ranging from 25 mg to 150 mg) in either the upper arm or buttocks on the date that your next injection was scheduled. Thereafter, you will receive an injection (ranging from 25 mg to 150 mg) in either the upper arm or buttocks once a month.<br />Depending on your symptoms, your doctor may increase or decrease the amount of medicine you receive by one dose level at the time of your scheduled monthly injection.<br />Patients with kidney problems<br />Your doctor may adjust your dose of this medicine based on your kidney function. If you have mild kidney problems your doctor may give you a lower dose. If you have moderate or severe kidney problems this medicine should not be used.<br />Elderly<br />Your doctor may reduce your dose of this medicine if your kidney function is reduced.<br />If you are given more Invega&reg; Sustenna &reg; than needed<br />This medicine will be given to you under medical supervision; it is, therefore, unlikely that you will be given too much.<br />Patients who have been given too much paliperidone may experience the following symptoms:<br />drowsiness or sedation, fast heart rate, low blood pressure, an abnormal electrocardiogram (electrical tracing of the heart), or slow or abnormal movements of the face, body, arms or legs.<br />If you stop using Invega&reg; Sustenna &reg;<br />If you stop receiving your injections, you will lose the effects of the medicine. You should not stop using this medicine unless told to do so by your doctor as your symptoms may return.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Tell your doctor immediately if you:</strong><br />&bull; experience blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty breathing. If you notice any of these symptoms seek medical advice immediately.<br />&bull; have dementia and experience a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke.<br />&bull; experience fever, muscle stiffness, sweating or a lowered level of consciousness (a disorder called &ldquo;Neuroleptic Malignant Syndrome&rdquo;). Immediate medical treatment may be needed.<br />&bull; are a man and experience prolonged or painful erection. This is called priapism. Immediate medical treatment may be needed.<br />&bull; experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of paliperidone may be needed.<br />&bull; experience a severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes drop in blood pressure (amounting to an &lsquo;anaphylactic reaction&rsquo;). Even if you have previously tolerated oral risperidone or oral paliperidone, rarely allergic reactions occur after receiving injections of paliperidone.<br />&bull; are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine. During an operation on the eye for cloudiness of the lens (cataract), the iris (the coloured part of the eye) may become floppy during surgery (known as &ldquo;floppy iris syndrome&rdquo;) that may lead to eye damage.<br />&bull; are aware of having dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood.<br />The following side effects may happen:<br />Very common side effects: may affect more than 1 in 10 people<br />&bull; difficulty falling or staying asleep.<br /><strong>Common side effects: may affect up to 1 in 10 people</strong><br />&bull; common cold symptoms, urinary tract infection, feeling like you have the flu<br />&bull; Invega&reg; Sustenna &reg; can raise your levels of a hormone called &ldquo;prolactin&rdquo; found on a blood test (which may or may not cause symptoms). When symptoms of high prolactin occur, they may include (in men) breast swelling, difficulty in getting or maintaining erections, or other sexual dysfunction; (in women) breast discomfort, leakage of milk from the breasts, missed menstrual periods, or other problems with your cycle<br />&bull; high blood sugar, weight gain, weight loss, decreased appetite<br />&bull; irritability, depression, anxiety<br />&bull; parkinsonism: This condition may include slow or impaired movement, sensation of stiffness or tightness of the muscles (making your movements jerky), and sometimes even a sensation of movement &quot;freezing up&quot; and then restarting. Other signs of parkinsonism include a slow shuffling walk, a tremor while at rest, increased saliva and/or drooling, and a loss of expression on the face.<br />&bull; restlessness, feeling sleepy, or less alert<br />&bull; dystonia: This is a condition involving slow or sustained involuntary contraction of muscles. While it can involve any part of the body (and may result in abnormal posture), dystonia often involves muscles of the face, including abnormal movements of the eyes, mouth, tongue or jaw.<br />&bull; dizziness<br />&bull; dyskinesia: This is a condition involving involuntary muscle movements, and can include repetitive, spastic or writhing movements, or twitching.<br />&bull; tremor (shaking)<br />&bull; headache<br />&bull; rapid heart rate<br />&bull; high blood pressure<br />&bull; cough, stuffy nose<br />&bull; abdominal pain, vomiting, nausea, constipation, diarrhoea, indigestion, toothache<br />&bull; increased liver transaminases in your blood<br />&bull; bone or muscle ache, back pain, joint pain<br />&bull; loss of menstrual periods<br />&bull; fever, weakness, fatigue (tiredness)<br />&bull; a reaction at the injection site, including itching, pain or swelling.<br /><strong>Uncommon side effects: may affect up to 1 in 100 people</strong><br />&bull; pneumonia, infection of the chest (bronchitis), infection of the breathing passages, sinus infection, bladder infection, ear infection, fungal infection of the nails, tonsillitis, infection of the skin<br />&bull; white blood cell count decreased, decrease in the type of white blood cells that help to protect you against infection, anaemia<br />&bull; allergic reaction<br />&bull; diabetes or worsening of diabetes, increased insulin (a hormone that controls blood sugar levels) in your blood<br />&bull; increased appetite<br />&bull; loss of appetite resulting in malnutrition and low body weight<br />&bull; high blood triglycerides (a fat), increased cholesterol in your blood<br />&bull; sleep disorder, elated mood (mania), decreased sexual drive, nervousness, nightmares<br />&bull; tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body). Tell your doctor immediately if you experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of this medicine may be needed.<br />&bull; fainting, a restless urge to move parts of your body, dizziness upon standing, disturbance in attention, problems with speech, loss or abnormal sense of taste, reduced sensation of skin to pain and touch, a sensation of tingling, pricking, or numbness of skin<br />&bull; blurry vision, eye infection or &quot;pink eye&quot;, dry eye<br />&bull; sensation of spinning (vertigo), ringing in the ears, ear pain<br />&bull; an interruption in conduction between the upper and lower parts of the heart, abnormal electrical conduction of the heart, prolongation of the QT interval from your heart, rapid heartbeat upon standing, slow heart rate, abnormal electrical tracing of the heart (electrocardiogram or ECG), a fluttering or pounding feeling in your chest (palpitations)<br />&bull; low blood pressure, low blood pressure upon standing (consequently, some people taking this medicine may feel faint, dizzy, or may pass out when they stand up or sit up suddenly)<br />&bull; shortness of breath, sore throat, nosebleeds<br />&bull; abdominal discomfort, stomach or intestinal infection, difficulty swallowing, dry mouth<br />&bull; excessive passing of gas or wind<br />&bull; increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, increased liver enzymes in your blood<br />&bull; hives (or &quot;nettle rash&quot;), itching, rash, hair loss, eczema, dry skin, skin redness, acne, abscess under the skin<br />&bull; an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown<br />&bull; muscle spasms, joint stiffness, muscle weakness<br />&bull; incontinence (lack of control) of urine, frequent passing of urine, pain when passing urine<br />&bull; erectile dysfunction, ejaculation disorder, missed menstrual periods or other problems with your cycle (females), development of breasts in men, sexual dysfunction, breast pain, leakage of milk from the breasts<br />&bull; swelling of the face, mouth, eyes, or lips, swelling of the body, arms or legs<br />&bull; an increase in body temperature<br />&bull; a change in the way you walk<br />&bull; chest pain, chest discomfort, feeling unwell<br />&bull; hardening of the skin<br />&bull; fall.<br /><strong>Rare side effects: may affect up to 1 in 1,000 people</strong><br />&bull; eye infection<br />&bull; skin inflammation caused by mites, flaky itchy scalp or skin<br />&bull; increase in eosinophils (a type of white blood cell) in your blood<br />&bull; decrease in platelets (blood cells that help you stop bleeding)<br />&bull; shaking of the head<br />&bull; inappropriate secretion of a hormone that controls urine volume<br />&bull; sugar in the urine<br />&bull; life threatening complications of uncontrolled diabetes<br />&bull; low blood sugar<br />&bull;excessive drinking of water<br />&bull;not moving or responding while awake (catatonia)<br />&bull;confusion<br />&bull;sleep walking<br />&bull;lack of emotion<br />&bull;inability to reach orgasm<br />&bull;neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever, andsevere muscle stiffness), blood vessel problems in the brain, including sudden loss of bloodsupply to brain (stroke or &quot;mini&quot; stroke), unresponsive to stimuli, loss of consciousness, lowlevel of consciousness, convulsion (fits), balance disorder<br />&bull;abnormal coordination<br />&bull;glaucoma (increased pressure within the eyeball)<br />&bull;problems with movement of your eyes, eye rolling, oversensitivity of the eyes to light, increasedtears, redness of the eyes<br />&bull;atrial fibrillation (an abnormal heart rhythm), irregular heartbeat<br />&bull;blood clot in the lungs causing chest pain and difficulty in breathing. If you notice any of thesesymptoms seek medical advice immediately<br />&bull;blood clots in the veins especially in the legs (symptoms include swelling, pain and redness inthe leg). If you notice any of these symptoms seek medical advice immediately<br />&bull;flushing<br />&bull;trouble breathing during sleep (sleep apnoea)<br />&bull;lung congestion, congestion of breathing passages<br />&bull;crackly lung sounds, wheezing<br />&bull;inflammation of the pancreas, swollen tongue, stool incontinence, very hard stool<br />&bull;a blockage in the bowels<br />&bull;chapped lips<br />&bull;rash on skin related to drug, thickening of skin, dandruff<br />&bull;breakdown of muscle fibers and pain in muscles (rhabdomyolysis)<br />&bull;joint swelling<br />&bull;inability to pass urine<br />&bull;breast discomfort, enlargement of the glands in your breasts, breast enlargement<br />&bull;vaginal discharge<br />&bull;priapism (a prolonged penile erection that may require surgical treatment)<br />&bull;very low body temperature, chills, feeling thirsty<br />&bull;symptoms of drug withdrawal<br />&bull;accumulation of pus caused by infection at injection site, deep skin infection, a cyst at injectionsite, bruising at injection site.</p><p><br /><strong>Not known: frequency cannot be estimated from the available data</strong><br />&bull;dangerously low numbers of a certain type of white blood cell needed to fight infection in yourblood<br />&bull;severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness ofbreath, itching, skin rash and sometimes drop in blood pressure<br />&bull;dangerously excessive intake of water<br />&bull;sleep-related eating disorder<br />&bull;coma due to uncontrolled diabetes<br />&bull;decreased oxygen in parts of your body (because of decreased blood flow)<br />&bull;fast, shallow breathing, pneumonia caused by inhaling food, voice disorder<br />&bull;lack of bowel muscle movement that causes blockage<br />&bull;yellowing of the skin and the eyes (jaundice)<br />&bull;severe or life-threatening rash with blisters and peeling skin that may start in and around themouth, nose, eyes and genitals and spread to other areas of the body (Stevens-Johnsonsyndrome or toxic epidermal necrolysis)<br />&bull;serious allergic reaction with swelling that may involve the throat and lead to difficultybreathing<br />&bull;skin discolouration&bull;abnormal posture&bull;newborn babies born to mothers who have taken Invega&reg; Sustenna &reg; during pregnancy may experience side effects of the drug and/or withdrawal symptoms, such as irritability, slow, or sustained muscle contractions, shaking, sleepiness, breathing, or feeding problems&bull;a decrease in body temperature&bull;dead skin cells at the injection site and an ulcer at the injection site.&bull;hyponatraemia<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.<br /><strong>To report any Side Effect(s):</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="1132" height="450" vspace="0" hspace="0" border="0" style="width:1132px;height:450px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.<br />Store below 30&deg;C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Invega&reg; Sustenna &reg; contains</strong><br />The active substance is paliperidone.<br />Each Invega&reg; Sustenna &reg; 25 mg pre-filled syringe contains 39 mg paliperidone palmitate in 0.25 mL.<br />Each Invega&reg; Sustenna &reg; 50 mg pre-filled syringe contains 78 mg paliperidone palmitate in 0.5 mL.<br />Each Invega&reg; Sustenna &reg; 75 mg pre-filled syringe contains 117 mg paliperidone palmitate in 0.75 mL.<br />Each Invega&reg; Sustenna &reg; 100 mg pre-filled syringe contains 156 mg paliperidone palmitate in 1 mL.<br />Each Invega&reg; Sustenna &reg; 150 mg pre-filled syringe contains 234 mg paliperidone palmitate in 1.5 mL.<br /><br />The other ingredients are:<br />Polysorbate 20<br />Polyethylene glycol 4000<br />Citric acid monohydrate<br />Disodium hydrogen phosphate anhydrous<br />Sodium dihydrogen phosphate monohydrate<br />Sodium hydroxide (for pH adjustment)<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Invega® Sustenna ® is a white to off-white prolonged release suspension for injection in a pre-filled syringe.
Each pack contains 1 pre-filled syringe and 2 needles.
Treatment initiation pack:
Each pack contains 1 pack of Invega® Sustenna ® 150 mg and 1 pack of Invega® Sustenna ® 100 mg.
Not all pack sizes may be marketed.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Janssen-Cilag International NV<br />Turnhoutseweg 30<br />B-2340 Beerse<br />Belgium</p><p><br /><strong>Manufacturer</strong><br />Janssen Pharmaceutica NV<br />Turnhoutseweg 30<br />B-2340 Beerse<br />Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 25 May 2023.

To contact us , please visit our website www.janssen.com/contact-us

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي حقن إنفيجا&reg; ساستينا&reg; على المادة الفعالة باليبيريدون التي تنتمي إلى فئة الأدوية المضادة للذهان، ويستخدم كعلاج مستديم لأعراض الفصام للمرضى البالغين المستقرين على الباليبيريدون أو الريسبيريدون.</p><p>&nbsp;</p><p dir="RTL">إذا كنت قد أبديت استجابة تجاه الباليبيريدون أو الريسبيريدون في الماضي، وكان لديك أعراض تتراوح بين الخفيفة والمتوسطة فقد يبدأ طبيبك العلاج بإنفيجا&reg; ساستينا&reg; دون الحاجة إلى أن تكون مستقرًا في السابق على الباليبيريدون أو الريسبيريدون.</p><p>&nbsp;</p><p dir="RTL">الفصام هو مرض لديه أعراض &quot;إيجابية&quot; وأعراض &quot;سلبية&quot;. وتعني الأعراض الإيجابية الزيادة في الأعراض التي لا تكون موجودة عادةً. على سبيل المثال، قد يسمع الشخص المصاب بالفصام أصواتًا أو قد يرى أشياء غير موجودة (يُطلق على هذا الهذيان)، أو قد يعتقد في أشياء غير حقيقية (يُطلق على هذا الأوهام) أو قد يشعر بالريبة تجاه الآخرين بشكل غير معتاد. أما الأعراض السلبية فتعني النقص في السلوكيات أو المشاعر الموجودة عادةً. على سبيل المثال، قد يبدو الشخص المصاب بالفصام انطوائيًا، كما أنه قد لا يستجيب عاطفيًا على الإطلاق أو قد يعاني من الصعوبة في التحدث بطريقة واضحة ومنطقية. وقد يشعر أيضًا الأشخاص الذين يعانون من هذا المرض بالاكتئاب أو القلق أو الذنب أو التوتر.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يساعد إنفيجا&reg; ساستينا&reg; في تخفيف أعراض المرض لديك ومنع تلك الأعراض من الظهور مجددًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم إنفيجا</strong><strong>&reg;</strong><strong> </strong><strong>&nbsp;ساستينا &reg; </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه مادة &quot;الباليبيريدون&quot; أو أي من المكونات الأخرى في الدواء (مدرجة في القسم&nbsp;6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه الأدوية الأخرى المضادة للذهان بما في ذلك مادة الريسبيريدون.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل استخدام إنفيجا&reg; ساستينا&reg;.</p><p dir="RTL">لم تتم دراسة هذا الدواء على المرضى كبار السن الذين يعانون من الخرف. ومع ذلك، فإن المرضى كبار السن الذين يعانون من الخرف, الذين يُعالجون بأنواع أخرى مشابهة لهذا الدواء، قد تزيد لديهم مخاطر الإصابة بالسكتة الدماغية أو الموت (انظر القسم&nbsp;4، الآثار الجانبية المحتملة).</p><p>&nbsp;</p><p dir="RTL">جميع الأدوية لها آثار جانبية، وبعض الآثار الجانبية لهذا الدواء قد تزيد أعراض بعض الحالات الطبية الأخرى سوءًا. لأجل ذلك السبب، من المهم مناقشة أي من الحالات التالية التي يُحتمل أن تسوء أثناء العلاج بهذا الدواء مع طبيبك:</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض باركنسون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم تشخيصك من قبل بحالة أعراضها تتضمن ارتفاعًا في درجة الحرارة وتصلب العضلات (المعروف أيضًا باسم المتلازمة الخبيثة للدواء المضاد للذهان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تعرضت في السابق لحركات غير طبيعية في اللسان أو الوجه (خلل الحركة المتأخر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أنك تعاني من انخفاض في مستويات خلايا الدم البيضاء في الماضي (التي قد تكون ناجمة عن أدوية أخرى أو لا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السكر أو عُرضة للإصابة به</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من سرطان الثدي أو كان لديك ورم في الغدة النخامية في الدماغ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض في القلب أو تتلقى علاجًا لمرض القلب الذي يعرضك للإصابة بانخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض ضغط الدم عند الوقوف أو النهوض بشكل مفاجئ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالصرع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الانتصاب لفترات طويلة و/أو ألم عند الانتصاب</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>إذا كنت تعاني من مشكلات في السيطرة على درجة حرارة الجسم الأساسية أو عند الارتفاع الزائد في درجة الحرارة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مستوى عالٍ بشكل مفرط من هرمون البرولاكتين في الدم أو إذا كنت مصابًا بورم محتمل معتمدعلى هرمون البرولاكتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أنت أو أي شخص آخر في عائلتك من جلطات دموية، حيث إن مضادات الذهان مرتبطة بتكوُّن جلطات الدم.</p><p>&nbsp;</p><p dir="RTL">إذا كنت تعاني من أي من هذه الحالات، يُرجى التحدث مع الطبيب المعالج لك لأنه قد يحتاج إلى تعديل جرعتك أو متابعتك لفترة من الزمن.</p><p>&nbsp;</p><p>نادرًا جدًا ما يحدث انخفاض شديد في أعداد نوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم لدى المرضى الذين يستخدمون هذا الدواء؛ لذلك قد يفحص طبيبك عدد خلايا الدم البيضاء.</p><p>&nbsp;</p><p dir="RTL">وحتى إذا كنت قد تحملت مسبقًا تلقي الباليبيريدون أو الريسبيريدون عن طريق الفم، فنادرًا ما تحدث ردود فعل تحسسية بعد الحقن بإنفيجا&reg; ساستينا&reg;. اطلب العناية الطبية مباشرة إذا كنت تعاني من طفح جلدي أو تورم في الحلق أو الحكة أو مشكلات في التنفس حيث يمكن أن تكون هذه علامات على رد فعل تحسسي خطير.</p><p>&nbsp;</p><p dir="RTL">قد يتسبب هذا الدواء في زيادة وزنك. قد تؤثر زيادة الوزن الكبيرة سلبًا على صحتك. يتعين على طبيبك مراقبة وزنك بانتظام.</p><p>&nbsp;</p><p>قد لوحظ ظهور مرض السكري أو تفاقم السكري موجود سابقًا في المرضى الذين يتناولون هذا الدواء، لذا ينبغي لطبيبك التحقق من علامات ارتفاع نسبة السكر في الدم. وتجب مراقبة نسبة الجلوكوز في الدم لدى المرضى المصابين بالسكّري من قبل بانتظام.</p><p dir="RTL">نظرًا إلى أن هذا الدواء قد يخفض رغبتك في التقيؤ، فيوجد احتمال أنه قد يُخفي استجابة الجسم الطبيعية تجاه ابتلاع المواد السامة والحالات الطبية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند إجراء عملية جراحية في العين لإزالة عتامة عدسة العين (المياه البيضاء)، قد لا يزداد حجم حدقة العين (الدائرة السوداء في منتصف العين) كما هو مطلوب. وقد تصبح أيضًا القزحية (الجزء الملون من العين) رخوة أثناء الجراحة مما قد يتسبب في إصابة العين بالأضرار. وإذا كنت تخطط لإجراء عملية جراحية في عينيك، فتأكد من إبلاغ طبيب العيون المعالج من أنك تتناول هذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">هذا الدواء غير مخصص للأشخاص الذين تقل أعمارهم عن 18 سنة .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>وإنفيجا</strong><strong>&reg;</strong><strong> </strong><strong>ساستينا</strong><strong> &reg; </strong></p><p dir="RTL">يُرجى إبلاغ طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">تلقي هذا الدواء مع دواء كاربامازيبين (دواء مضاد للصرع ومثبت للمزاج) قد يحتاج إلى تغيير جرعتك من هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">نظرًا إلى أن هذا الدواء يعمل في المقام الأول في الدماغ، فإن التداخل مع الأدوية الأخرى التي تعمل في الدماغ مثل الأدوية النفسية الأخرى، والمواد الأفيونية، ومضادات الهيستامين، والأدوية المنوِمة يمكن أن يسبب تفاقم الآثار الجانبية مثل النعاس أو غيره من الآثار الجانبية على الدماغ.</p><p>&nbsp;</p><p dir="RTL">بما أن هذا الدواء قد يتسبب في خفض ضغط الدم، يجب توخي الحذر عند استخدام هذا الدواء مع الأدوية الأخرى التي تعمل على خفض ضغط الدم.</p><p>&nbsp;</p><p dir="RTL">ويمكن أن يقلل هذا الدواء من تأثير الأدوية التي تُعالج مرض باركنسون ومتلازمة تململ الساقين (على سبيل المثال، الليفودوبا).</p><p>&nbsp;</p><p dir="RTL">قد يتسبب هذا الدواء في ظهور الرسم الكهربي للقلب (ECG) بشكل غير طبيعي، حيث تستغرق النبضة الكهربائية مدة طويلة لكي تنتقل خلال جزء معين في القلب (يُعرف أيضًا باسم &quot;إطالة فترة QT&quot;). تشمل الأدوية الأخرى التي لها هذا التأثير بعض الأدوية المستخدمة في علاج عدم انتظام ضربات القلب أو علاج العدوى، بالإضافة إلى الأدوية المضادة للذهان الأخرى.</p><p>&nbsp;</p><p dir="RTL">إذا كنت عُرضة لحدوث التشنجات، فقد يزيد هذا الدواء احتمال تعرضك لها. تشمل الأدوية الأخرى التي لديها هذا التأثير بعض الأدوية المستخدمة في علاج الاكتئاب أو علاج العدوى، بالإضافة إلى الأدوية المضادة للذهان الأخرى.</p><p>&nbsp;</p><p dir="RTL">يجب استخدام إنفيجا&reg; ساستينا&reg; بحذر مع الأدوية التي تزيد من نشاط الجهاز العصبي المركزي (المنشطات النفسية مثل ميثيل الفينيدات).</p><p dir="RTL"><strong>إنفيجا</strong><strong>&reg; </strong><strong>ساستينا</strong><strong> &reg;</strong><strong> مع</strong><strong> </strong><strong>الكحول</strong></p><p dir="RTL">يحظر شرب الكحول .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين، أو تعتقدين بأنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري طبيبكِ أو الصيدلي للحصول على النصيحة قبل تناول هذا الدواء. يجب ألا تستخدمي هذا الدواء أثناء الحمل ما لم تتم مناقشة ذلك مع طبيبكِ. وقد تحدث الأعراض التالية لدى الأطفال حديثي الولادة لأمهات استخدمن الباليبيريدون في الثلث الأخير من الحمل (الأشهر الثلاثة الأخيرة من حملهن): رعشة وتصلب العضلات و/أو الضعف والنعاس والهياج ومشكلات في التنفس وصعوبة في الرضاعة. إذا ظهرت أي من هذه الأعراض على طفلك، فعليك الاتصال بطبيبك.</p><p>&nbsp;</p><p dir="RTL">يمكن أن ينتقل هذا الدواء من الأم إلى الطفل عبر لبن / حليب الأم، وقد يضر بالطفل. لذا، يجب عدم الإرضاع عند استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد يحدث دوار، وشعور بتعب شديد، ومشكلات في الرؤية أثناء العلاج باستخدام هذا الدواء (انظر القسم&nbsp;4). يجب مراعاة ذلك في الحالات التي تتطلب يقظة كاملة، على سبيل المثال، عند قيادة سيارة أو التعامل مع الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>إنفيجا </strong><strong>&reg; </strong><strong>ساستينا</strong><strong> &reg; </strong><strong>&nbsp;على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1&nbsp;ملليمول صوديوم (23&nbsp;مجم) لكل جرعة، أي أن الدواء يُعد &quot;خاليًا من الصوديوم&quot; في الأساس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُعطى لك هذا الدواء من قِبل طبيبك أو أخصائي رعاية صحية آخر. سيخبرك الطبيب متى تحتاج حقنتك التالية. من المهم عدم تفويت موعد جرعتك المقرَر. إذا لم تستطع الحفاظ على موعدك مع الطبيب، فاحرص على الاتصال به على الفور لتحديد موعد آخر في أقرب وقت ممكن.</p><p>&nbsp;</p><p dir="RTL">ستتلقى الحقنة الأولى (150&nbsp;مجم)، والحقنة الثانية (100&nbsp;مجم) من هذا الدواء في الجزء العلوي من الذراع، بفاصل أسبوع تقريبًا بين الحقنتين. بعد ذلك، ستتلقى حقنة (تتراوح بين 25&nbsp;مجم و150&nbsp;مجم) إما في الجزء العلوي من الذراع أو في الأرداف مرة واحدة في الشهر.</p><p>&nbsp;</p><p dir="RTL">إذا قام طبيبك بتحويلك من حقنة الريسبيريدون مديدة المفعول إلى هذا الدواء، فستتلقى الحقنة الأولى من هذا الدواء (تتراوح بين 25&nbsp;مجم و150&nbsp;مجم) إما في الجزء العلوي من الذراع أو في الأرداف في التاريخ الذي كان مقررًا لحقنتك التالية. بعد ذلك، ستتلقى حقنة (تتراوح بين 25&nbsp;مجم و150&nbsp;مجم) إما في الجزء العلوي من الذراع أو في الأرداف مرة واحدة في الشهر.</p><p>&nbsp;</p><p dir="RTL">وفقًا لما ستبديه من أعراض، فإن طبيبك قد يزيد أو يخفض كمية الدواء التي تتلقاها بمستوى جرعة واحدة في الموعد المقرر لحقنتك الشهرية.</p><p>&nbsp;</p><p dir="RTL"><u>المرضى الذين يعانون من مشاكل في الكلى</u></p><p dir="RTL">قد يُعدّل طبيبك الجرعة التي تتناولها من هذا الدواء بناء على وظائف الكلى لديك. إذا كانت مشكلات الكلى لديك خفيفة، فقد يعطيك طبيبك جرعة أقل من هذا الدواء. أما إذا كانت مشكلات الكلى لديك متوسطة أو شديدة، فلا يجب استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><u>كبار السن</u></p><p dir="RTL">قد يقلل طبيبك الجرعة التي تحصل عليها من هذا الدواء في حالة تدهور وظائف الكلى.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أُعطيت إنفيجا&reg; ساستينا&reg;</strong><strong> </strong><strong>بكمية أكبر من اللازم</strong></p><p dir="RTL">سيتم إعطاؤك هذا الدواء تحت إشراف طبي، لذا من غير المحتمل أن يتم إعطاؤك جرعة أكبر من اللازم.</p><p>&nbsp;</p><p dir="RTL">قد يتعرض المرضى الذين تم إعطاؤهم جرعة أكبر من الباليبيريدون للأعراض التالية:</p><p dir="RTL">النعاس أو الخدر أو ضربات القلب السريعة أو انخفاض ضغط الدم أو ظهور الرسم الكهربي (التتبع الكهربي) للقلب بشكل غير طبيعي أو حدوث حركات بطيئة أو غير طبيعية في الوجه أو الجسم أو الذراعين أو الساقين.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام إنفيجا&reg; ساستينا&reg;</strong></p><p dir="RTL">إذا توقفت عن أخذ الحقن، فستفقد تأثيرات الدواء. يجب عدم التوقف عن استخدام هذا الدواء إلا بطلب من طبيبك حيث قد تظهر الأعراض مجددًا.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من عدم إصابة الجميع بها.</p><p>&nbsp;</p><p dir="RTL"><strong>اتصل بطبيبك على الفور إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت للإصابة بجلطات دموية في الأوردة، لا سيما في الأرجل (وتتضمن الأعراض تورم الأرجل والشعور بالألم فيها واحمرارها)، والتي قد تنتقل إلى الرئتين عبر الأوعية الدموية مسببة ألمًا في الصدر وصعوبة في التنفس. إذا لاحظت أي من هذه الأعراض، فاطلب المشورة الطبية على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من الخرف أو واجهت تغييرًا مفاجئًا في حالتك العقلية أو ضعفًا مفاجئًا أو خدرًا مفاجئًا في الوجه والذراعين والأرجل وخصوصًا في جانب واحد، أو صعوبة في الكلام، حتى ولو لفترة زمنية قصيرة. قد تكون هذه الأمور علامات على السكتة الدماغية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أُصبت بالحمى أو تصلب العضلات أو التعرق أو انخفاض مستوى الوعي (اضطراب يسمى &quot;المتلازمة الخبيثة للدواء المضاد للذهان&quot;). وقد يلزم توفير العلاج الطبي الفوري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت ذكرًا وتعاني من الانتصاب لفترات طويلة أو الانتصاب المؤلم. يسمى هذا القُسَاح. وقد يلزم توفير العلاج الطبي الفوري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت لحركات إيقاعية لا إرادية في اللسان والفم والوجه. قد تستلزم الحالة التوقف عن دواء الباليبيريدون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من رد فعل تحسسي حاد مصحوب بحمى وتورم في الفم أو الوجه أو الشفاه أو اللسان وضيق في التنفس وحكة وطفح جلدي وأحيانًا حدوث انخفاض في ضغط الدم (يرتقي إلى أن يكون &quot;تفاعل تحسسي &quot;). وحتى إذا كنت قد تحملت مسبقًا تلقي الباليبيريدون أو الريسبيريدون عن طريق الفم، فنادرًا ما تحدث ردود فعل تحسسية بعد الحقن بباليبيريدون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط لإجراء عملية جراحية في عينيك، فتأكد من إبلاغ طبيب العيون المعالج من أنك تتناول هذا الدواء. أثناء إجراء عملية في العين لإزالة عتامة عدسة العين (المياه البيضاء)، قد تصبح القزحية (الجزء الملون من العين) رخوة أثناء الجراحة (حالة معروفة باسم &quot;ترهُّل القزحية الجراحي&quot;) مما قد يتسبب في إصابة العين بالأضرار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت على دراية بانخفاض أعداد نوع معين بشكل خطير من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم.</p><p>&nbsp;</p><p dir="RTL">قد تظهر الآثار الجانبية التالية:</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا: قد تؤثر على أكثر من 1 من كل 10&nbsp;أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم أو الاستغراق فيه.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة: قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض نزلات البرد الشائعة، وعدوى في المسالك البولية، والشعور كأنك مصاب بالإنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يرفع إنفيجا&reg; ساستينا&reg; من مستويات هرمون يُطلق عليه &quot;البرولاكتين&quot; الموجود في عينة تحليل الدم (الذي قد يؤدي إلى ظهور الأعراض أو لا يؤدي إلى ظهورها). عند ظهور أعراض ارتفاع هرمون البرولاكتين، قد تشمل: (لدى الذكور) تورم الثدي أو صعوبة في الانتصاب أو استمرار الانتصاب أو خلل الوظائف الجنسية الأخرى، (لدى الإناث) عدم الشعور براحة في الثدي أو تسرب اللبن/ الحليب من الثدي أو انقطاع الدورة الشهرية أو حدوث مشاكل أخرى في الدورة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم، زيادة الوزن، فقدان الوزن، انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانفعالية، والاكتئاب، والقلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الباركنسونية: قد تتضمن هذه الحالة: بطء الحركة أو ضعفًا فيها، والإحساس بتصلب العضلات أو تضامها (تجعل الحركات متشنجة)، وأحيانًا حتى الإحساس &quot;بتجمد&quot; في الحركة ثم البدء ثانية. تتضمن العلامات الأخرى لداء باركنسون البطء في تبديل خطوات المشي و/أو الرعشة في وقت الاسترخاء و/أو تزايد و/أو سيلان اللعاب، وفقدان التعبيرات على الوجه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الراحة أو الشعور بالنعاس أو قلة الانتباه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل التوتر العضلي: عبارة عن حالة مرضية مصحوبة بانقباض لاإرادي بطيء أو مستمر في العضلات. في حين أن خلل التوتر العضلي يمكن أن يصيب أي جزء من الجسم (وقد يؤدي إلى وضعية جسدية غير طبيعية )، غالبًا ما يؤثر هذا المرض على عضلات الوجه مثل حدوث حركات غير طبيعية في العينين أو الفم أو اللسان أو الفك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الحركة: عبارة عن حالة مرضية مصحوبة بحركات لا إرادية في العضلات، وقد تتضمن حركات متكررة أو حركات تشنجية أو حركات توجع من الألم، أو النفضان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاف (الارتعاش)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة معدل ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال، وانسداد الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم في البطن، أو التقيؤ أو الشعور بالغثيان أو الإمساك أو الإسهال أو عسر الهضم أو ألم الأسنان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات ناقلات أمينات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العظام أو العضلات، آلام الظهر، آلام المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع الدورة الشهرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، والضعف، والإعياء (الإرهاق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبداء رد فعل في موضع الحقن يتضمن الحكة أو الألم أو التورم.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة: قد تؤثر على ما يصل إلى 1 من كل 100 شخصٍ</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي ، والعدوى في الصدر (التهاب الشعب الهوائية)، و العدوى في ممرات التنفس، و العدوى في الجيوب الأنفية، والعدوى في المثانة، و العدوى في الأذن، والعدوى الفطرية في الأظافر، والتهاب اللوزتين، و العدوى في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء، وانخفاض نوع معين من خلايا الدم البيضاء التي تساعد في حمايتك من العدوى، والأنيميا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بمرض السكري أو تفاقمه، وزيادة الأنسولين (هرمون يتحكم في مستويات السكر في الدم) في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية الذي يؤدي إلى سوء التغذية وانخفاض وزن الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة الدهون الثلاثية في الدم (نوع من أنواع دهون الدم )، زيادة الكوليسترول في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم، والمزاج المتهيج (الهوس)، وانخفاض الرغبة الجنسية، والعصبية، والكوابيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الحركة المتأخر (نفضان أو حركات ارتعاشية لا يمكنك بسببها التحكم في وجهك أو لسانك أو الأجزاء الأخرى من جسمك). أخبر طبيبك على الفور إذا تعرضت لحركات إيقاعية لا إرادية في اللسان والفم والوجه. لذا قد تستلزم الحالة التوقف عن هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، الرغبة المستمرة في تحريك أجزاء الجسم، دوخة عند القيام، حدوث اضطراب في الانتباه، مشاكل في الكلام، فقدان أو &nbsp;تغير في حاسة التذوق، انخفاض إحساس الجلد بالألم واللمس، الإحساس بالتخدر أو الوخز أو تنميل الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية الضبابية، و العدوى في العين أو &quot;العين القرنفلية&quot;، وجفاف العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بعدم الاتزان (دوار)، وجود طنين في الأذنين، ألم في الأذن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع التوصيل بين الأجزاء العلوية والسفلية للقلب، وحدوث التوصيل الكهربي في القلب بشكل غير طبيعي، وإطالة فترة QT في القلب، وسرعة ضربات القلب عند الوقوف، وبطء معدل ضربات القلب، وحدوث التتبع الكهربي للقلب (الرسم الكهربي للقلب أو ECG) بشكل غير طبيعي، الشعور برفرفة أو ضربات عنيفة في صدرك (خفقان القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم أو انخفاض ضغط الدم عند الوقوف (وبناءً على ذلك، قد يشعر بعض الأشخاص الذين يتناولون هذا الدواء بالإغماء أو الدوخة أو قد يفقدون وعيهم عند الوقوف أو النهوض فجأة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس، والتهاب الحلق، ونزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الراحة في البطن، و العدوى في المعدة أو الأمعاء، وصعوبة في البلع، وجفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإخراج المفرط للغازات أو الرياح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة GGT (إنزيم كبدي يسمى ناقل جاما جلوتاميل) في الدم، زيادة إنزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (أو &quot;طفح القراص&quot;)، والحكة، والطفح الجلدي، وتساقط الشعر، والإكزيما، وجفاف الجلد، واحمرار الجلد، وحب الشباب، وخُراج تحت الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الكرياتين فسفوكيناز (CPK) في دمك، وهو إنزيم يخرج أحيانًا مع ارهاق العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات، وتيبس المفاصل، وضعف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سَلس (ضعف التحكم في) البول، التبول المتكرر، ووجود ألم عند التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الانتصاب، واضطراب في القذف، وانقطاع الدورة الشهرية أو حدوث مشكلات أخرى في الدورة لدي الإناث، وبروز الصدر لدى الرجال، وخلل في الوظيفة الجنسية، وألم في الثدي، وتسرب اللبن/الحليب من الثديين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الفم أو العينين أو الشفتين، أو تورم الجسم أو الذراعين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في درجة حرارة الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في طريقة مشيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الصدر، عدم الشعور بارتياح في الصدر، الشعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة: قد تؤثر على ما يصل إلى 1 من كل 1000 شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد الناجم عن العث، وميل الجلد للتقشر، وحكة في فروة الرأس أو الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في اليوزينيات (نوع من كرات الدم البيضاء) في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدموية (نوع من خلايا الدم تساعدك على وقف النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اهتزاز الرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفراز غير ملائم لهرمون يتحكم في كمية البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود سكر في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضاعفات المهددة للحياة الناتجة عن عدم انتظام معدلات السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفراط في شرب المياه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الحركة أو الاستجابة أثناء اليقظة (الجامود)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشوش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشي أثناء النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فتور العاطفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على الوصول إلى هزة الجماع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المتلازمة الخبيثة للدواء المضاد للذهان (الارتباك، وانخفاض الوعي أو فقدانه، والحمى الشديدة، وتصلب حاد في العضلات)، ومشكلات الأوعية الدموية في الدماغ، بما في ذلك الفقدان المفاجئ لتدفق الدم إلى الدماغ (السكتة الدماغية أو السكتة الدماغية &quot;البسيطة&quot;)، وعدم الاستجابة للمنبهات، وفقدان الوعي، وانخفاض مستوى الوعي، والاختلاج (النوبات)، واضطراب التوازن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم تناسق الحركة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المياه الزرقاء (ارتفاع ضغط مقلة العين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في حركة العين، ودوران العين، وفرط حساسية العينين للضوء، وزيادة الدموع، واحمرار العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رجفان أذيني (ضربات قلب غير طبيعية)، عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في الرئتين مسببة ألمًا في الصدر وصعوبة في التنفس. إذا لاحظت أي من هذه الأعراض، فاطلب المشورة الطبية على الفور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في الأوردة، لا سيما في الأرجل (وتتضمن الأعراض تورم الأرجل والشعور بالألم فيها واحمرارها). إذا&nbsp;لاحظت أي من هذه الأعراض، فاطلب المشورة الطبية على الفور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أثناء النوم (انقطاع النفس أثناء النوم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الرئة، واحتقان ممرات التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصوات طقطقة في الرئة، ووجود أزيز عند التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس، وتورم اللسان، وسلس البراز، والبراز شديد الصلابة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد في الأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشقق الشفاه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي المرتبط بالدواء، وسماكة الجلد، وقشرة الرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انهيار الألياف العضلية وألم في العضلات (انحلال الربيدات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على إخراج البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بانزعاج في الثدي، وتضخم الغدد الموجودة في الثديين، وتضخم الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفرازات المهبلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القساح (عبارة عن انتصاب قضيبي مطول قد يتطلب معالجة جراحية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة حرارة الجسم للغاية، والقشعريرة، والشعور بالعطش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض التوقف عن الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع صديدي ناجم عن العدوى عند موضع الحقن، والعدوى &nbsp;الجلدية العميقة، وحدوث تكيس في موضع الحقن، ووجود كدمات في موضع الحقن.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار غير معروفة: لا يمكن تقدير التكرار من البيانات المتوفرة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد نوع معين بشكل خطير من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي حاد مصاحب بالإصابة بالحمى، أو حدوث تورم في الفم أو الوجه أو الشفاه أو اللسان، والإصابة بضيق النفس، والإصابة بالحكة، والإصابة بالطفح الجلدي وأحيانًا حدوث انخفاض في ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفراط في تناول الماء بشكل خطير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأكل المرتبطة بالنوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغيبوبة الناتجة عن عدم انضباط معدلات السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الأكسجين في أجزاء من الجسم (بسبب انخفاض تدفق الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنفس السريع والضحل، والالتهاب الرئوي الناجم عن استنشاق الطعام، واضطراب الصوت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم حركة عضلات الأمعاء الذي يسبب انسداد الأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين (اليرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد أو يهدد الحياة مع ظهور بثور وتقشر الجلد الذي قد يبدأ في وحول الفم والأنف والعينين والأعضاء التناسلية وينتشر إلى مناطق أخرى من الجسم (متلازمة ستيفنز جونسون أو تقشر الأنسجة المتموتة البشروية التسممي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي حاد مع تورم قد يشمل الحلق ويؤدي إلى صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وضعية جسدية غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يعاني الأطفال حديثي الولادة لأمهات تناولن إنفيجا&reg; ساستينا&reg; أثناء الحمل من آثار جانبية للدواء و/أو أعراض انسحاب، مثل الانفعالية، وتقلصات العضلات البطيئة أو المستمرة، والارتعاش، والنعاس، ومشكلات في التنفس أو التغذية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في درجة حرارة الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت خلايا الجلد في موضع الحقن وقرحة في موضع الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة الصوديوم فى الدم</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. ويتضمن ذلك أي آثار جانبية محتملة غير مُدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p><strong>للإبلاغ عن أي أثار جانبية: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:612px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: &nbsp;npc.drug@sfda.gov.sa&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp; <strong>دول الخليج العربي الأخرى</strong>:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp; &nbsp;الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المحدد على العبوة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إلى استخدامها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات إنفيجا&reg; ساستينا&reg;</strong></p><p dir="RTL">المادة الفعالة هي الباليبيريدون.</p><p dir="RTL">تحتوي كل محقنة معبأة مسبقًا بحجم 25&nbsp;مجم من إنفيجا&reg; ساستينا&reg; على 39&nbsp;مجم من الباليبيريدون بالميتات في 0.25 مل.</p><p dir="RTL">تحتوي كل محقنة معبأة مسبقًا بحجم 50&nbsp;مجم من إنفيجا&reg; ساستينا&reg; على 78&nbsp;مجم من الباليبيريدون بالميتات في 0.5 مل.</p><p dir="RTL">تحتوي كل محقنة معبأة مسبقًا بحجم 75&nbsp;مجم من إنفيجا&reg; ساستينا&reg; على 117&nbsp;مجم من الباليبيريدون بالميتات في 0.75 مل.</p><p dir="RTL">تحتوي كل محقنة معبأة مسبقًا بحجم 100&nbsp;مجم من إنفيجا&reg; ساستينا&reg; على 156&nbsp;مجم من الباليبيريدون بالميتات في 1 مل.</p><p dir="RTL">تحتوي كل محقنة معبأة مسبقًا بحجم 150&nbsp;مجم من إنفيجا&reg; ساستينا&reg; على 234&nbsp;مجم من الباليبيريدون بالميتات في 1.5 مل.</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">بوليسوربات 20</p><p dir="RTL">جليكول بولي إيثيلين 4000</p><p dir="RTL">أحادى هيدرات حمض الستريك</p><p dir="RTL">فوسفات ثنائي الصوديوم الهيدروجينية اللامائية</p><p dir="RTL">أحادي هيدرات فوسفات ثنائي هيدروجين الصوديوم</p><p dir="RTL">هيدروكسيد الصوديوم (لمعادلة درجة الحموضة)</p><p dir="RTL">ماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إنفيجا&reg; ساستينا&reg; هو معلَّق أبيض مائل إلى اللون العاجي ممتد المفعول للحقن في محقنة معبأة مسبقًا.</p><p>&nbsp;</p><p dir="RTL">كل عبوة تحتوي على محقنة معبأة مسبقًا واحدة، وإبرتين.</p><p>&nbsp;</p><p dir="RTL">عبوة بدء العلاج:</p><p dir="RTL">تحتوي كل عبوة على عبوة واحدة من إنفيجا&reg; ساستينا&reg; بحجم 150&nbsp;مجم، وعبوة واحدة من إنفيجا&reg; ساستينا&reg; بحجم 100&nbsp;مجم.</p><p>&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل الرخصة التسويقية</strong></p><p>جانسن سیلاج إنترناشونال ان فى</p><p>ترنهوتسويج- 30</p><p>بي- 2340</p><p dir="RTL">بیرس ، بلجیكا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنّعة</strong></p><p>جانسن فارماسوتيكا إن في</p><p>ترنهوتسويج 30،</p><p>بي 2340</p><p dir="RTL">بیرس ، بلجیكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر مراجعة لهذه النشرة في 25 مايو 2023.
للإتصال بنا، يرجى زيارة موقعنا على الويب www.janssen.com/contact-us

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Invega Sustenna 25 mg prolonged release suspension for injection
Invega Sustenna 50 mg prolonged release suspension for injection
Invega Sustenna 75 mg prolonged release suspension for injection
Invega Sustenna 100 mg prolonged release suspension for injection
Invega Sustenna 150 mg prolonged release suspension for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25 mg prolonged release suspension for injection
Each pre-filled syringe contains 39 mg paliperidone
palmitate in 0.25 mL equivalent to 25 mg
paliperidone.
50 mg prolonged release suspension for injection
Each pre-filled syringe contains 78 mg paliperidone
palmitate in 0.5 mL equivalent to 50 mg
paliperidone.
75 mg prolonged release suspension for injection
Each pre-filled syringe contains 117 mg
paliperidone palmitate in 0.75 mL equivalent to
75 mg paliperidone.
100 mg prolonged release suspension for injection Each pre-filled syringe contains 156 mg
paliperidone palmitate in 1 mL equivalent to
100 mg paliperidone.
150 mg prolonged release suspension for injection
Each pre-filled syringe contains 234 mg
paliperidone palmitate in 1.5 mL equivalent to
150 mg paliperidone.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged release suspension for injection.
The suspension is white to off-white. Thesuspension is pH neutral (approximately 7.0).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Invega Sustenna is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.</p><p>&nbsp;</p><p>In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Invega Sustenna may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Recommended initiation of Invega Sustenna is with a dose of 150 mg on treatment day 1 and 100 mg one week later (day 8), both administered in the deltoid muscle in order to attain therapeutic</p><p>&nbsp;</p><p>concentrations rapidly (see section 5.2). The third dose should be administered one month after the second initiation dose. The recommended monthly maintenance dose is 75 mg; some patients may benefit from lower or higher doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy. Patients who are overweight or obese may require doses in the upper range (see section 5.2). Following the second initiation dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle.</p><p>&nbsp;</p><p>Adjustment of the maintenance dose may be made monthly. When making dose adjustments, the prolonged release characteristics of Invega Sustenna should be considered (see section 5.2), as the full effect of maintenance doses may not be evident for several months.</p><p>&nbsp;</p><p><em>Switching from oral prolonged release paliperidone or oral risperidone to Invega Sustenna</em></p><p>Invega Sustenna should be initiated as described at the beginning of section 4.2 above. During monthly maintenance treatment with Invega Sustenna, patients previously stabilised on different doses of paliperidone prolonged release tablets can attain similar paliperdone steady-state exposure by injection. The Invega Sustenna maintenance doses needed to attain similar steady-state exposure are shown as follows:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Doses of paliperidone prolonged release tablets and Invega Sustenna needed to attain similar steady-state paliperidone exposure during maintenance treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Previous paliperidone prolonged release tablet dose</strong></p></td><td style="vertical-align:top"><p><strong>Invega Sustenna injection</strong></p></td></tr><tr><td style="vertical-align:top"><p>3 mg daily</p></td><td style="vertical-align:top"><p>25-50 mg monthly</p></td></tr><tr><td style="vertical-align:top"><p>6 mg daily</p></td><td style="vertical-align:top"><p>75 mg monthly</p></td></tr><tr><td style="vertical-align:top"><p>9 mg daily</p></td><td style="vertical-align:top"><p>100 mg monthly</p></td></tr><tr><td style="vertical-align:top"><p>12 mg daily</p></td><td style="vertical-align:top"><p>150 mg monthly</p></td></tr></tbody></table><p>&nbsp;</p><p>Previous oral paliperidone or oral risperidone can be discontinued at the time of initiation of treatment with Invega Sustenna. Some patients may benefit from gradual withdrawal. Some patients switching from higher paliperidone oral doses (e.g., 9-12 mg daily) to gluteal injections with Invega Sustenna may have lower plasma exposure during the first 6 months after the switch. Therefore, alternatively, it could be considered to give deltoid injections for the first 6 months.</p><p>&nbsp;</p><p><em>Switching from risperidone long acting injection to Invega Sustenna</em></p><p>When switching patients from risperidone long acting injection, initiate Invega Sustenna therapy in place of the next scheduled injection. Invega Sustenna should then be continued at monthly intervals. The one-week initiation dosing regimen including the intramuscular injections (day 1 and 8, respectively) as described in section 4.2 above is not required. Patients previously stabilised on different doses of risperidone long acting injection can attain similar paliperidone steady-state exposure during maintenance treatment with Invega Sustenna monthly doses according to the following:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Doses of risperidone long acting injection and Invega Sustenna needed to attain similar paliperidone exposure at steady-state</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Previous risperidone long acting injection dose</strong></p></td><td style="vertical-align:top"><p><strong>Invega Sustenna injection</strong></p></td></tr><tr><td style="vertical-align:top"><p>25 mg every 2 weeks</p></td><td style="vertical-align:top"><p>50 mg monthly</p></td></tr><tr><td style="vertical-align:top"><p>37.5 mg every 2 weeks</p></td><td style="vertical-align:top"><p>75 mg monthly</p></td></tr><tr><td style="vertical-align:top"><p>50 mg every 2 weeks</p></td><td style="vertical-align:top"><p>100 mg monthly</p></td></tr></tbody></table><p>&nbsp;</p><p>Discontinuation of antipsychotic medicinal products should be made in accordance with appropriate prescribing information. If Invega Sustenna is discontinued, its prolonged release characteristics must be considered. The need for continuing existing extrapyramidal symptoms (EPS) medicine should be re-evaluated periodically.</p><p>&nbsp;</p><p><u>Missed doses</u></p><p>&nbsp;</p><p><em>Avoiding missed doses</em></p><p>It is recommended that the second initiation dose of Invega Sustenna be given one week after the first dose. To avoid a missed dose, patients may be given the second dose 4 days before or after the</p><p>one-week (day 8) time point. Similarly, the third and subsequent injections after the initiation regimen are recommended to be given monthly. To avoid a missed monthly dose, patients may be given the injection up to 7 days before or after the monthly time point.</p><p>&nbsp;</p><p>If the target date for the second Invega Sustenna injection (day 8 &plusmn; 4 days) is missed, the recommended reinitiation depends on the length of time which has elapsed since the patient&#39;s first injection.</p><p>&nbsp;</p><p><em>Missed second initiation dose (&lt; 4 weeks from first injection)</em></p><p>If less than 4 weeks have elapsed since the first injection, then the patient should be administered the second injection of 100 mg in the deltoid muscle as soon as possible. A third Invega Sustenna injection of 75 mg in either the deltoid or gluteal muscles should be administered 5 weeks after the first injection (regardless of the timing of the second injection). The normal monthly cycle of injections in either the deltoid or gluteal muscle of 25 mg to 150 mg based on individual patient tolerability and/or efficacy should be followed thereafter.</p><p>&nbsp;</p><p><em>Missed second initiation dose (4-7 weeks from first injection)</em></p><p>If 4 to 7 weeks have elapsed since the first injection of Invega Sustenna, resume dosing with two injections of 100 mg in the following manner:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a deltoid injection as soon as possible</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; another deltoid injection one week later</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; resumption of the normal monthly cycle of injections in either the deltoid or gluteal muscle of 25 mg to 150 mg based on individual patient tolerability and/or efficacy.</p><p>&nbsp;</p><p><em>Missed second initiation dose (&gt; 7 weeks from first injection)</em></p><p>If more than 7 weeks have elapsed since the first injection of Invega Sustenna, initiate dosing as described for the initial recommended initiation of Invega Sustenna above.</p><p>&nbsp;</p><p><em>Missed monthly maintenance dose (1 month to 6 weeks)</em></p><p>After initiation, the recommended injection cycle of Invega Sustenna is monthly. If less than 6 weeks have elapsed since the last injection, then the previously stabilised dose should be administered as soon as possible, followed by injections at monthly intervals.</p><p>&nbsp;</p><p><em>Missed monthly maintenance dose (&gt; 6 weeks to 6 months)</em></p><p>If more than 6 weeks have elapsed since the last injection of Invega Sustenna, the recommendation is as follows:</p><p>&nbsp;</p><p><em>For patients stabilised with doses of 25 to 100 mg</em></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a deltoid injection as soon as possible at the same dose the patient was previously stabilised on</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; another deltoid injection (same dose) one week later (day 8)</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; resumption of the normal monthly cycle of injections in either the deltoid or gluteal muscle of 25 mg to 150 mg based on individual patient tolerability and/or efficacy.</p><p>&nbsp;</p><p><em>For patients stabilised with 150 mg</em></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a deltoid injection as soon as possible at the 100 mg dose</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; another deltoid injection one week later (day 8) at the 100 mg dose</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; resumption of the normal monthly cycle of injections in either the deltoid or gluteal muscle of 25 mg to 150 mg based on individual patient tolerability and/or efficacy.</p><p>&nbsp;</p><p><em>Missed monthly maintenance dose (&gt; 6 months)</em></p><p>If more than 6 months have elapsed since the last injection of Invega Sustenna, initiate dosing as described for the initial recommended initiation of Invega Sustenna above.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>Efficacy and safety in elderly &gt; 65 years have not been established.</p><p>&nbsp;</p><p>In general, recommended dosing of Invega Sustenna for elderly patients with normal renal function is the same as for younger adult patients with normal renal function. However, because elderly patients may have diminished renal function, dose adjustment may be necessary (see <em>Renal impairment </em>below for dosing recommendations in patients with renal impairment).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Invega Sustenna has not been systematically studied in patients with renal impairment (see section 5.2). For patients with mild renal impairment (creatinine clearance &ge; 50 to &lt; 80 mL/min),</p><p>recommended initiation of Invega Sustenna is with a dose of 100 mg on treatment day 1 and 75 mg one week later, both administered in the deltoid muscle. The recommended monthly maintenance dose is 50 mg with a range of 25 to 100 mg based on patient tolerability and/or efficacy.</p><p>&nbsp;</p><p>Invega Sustenna is not recommended in patients with moderate or severe renal impairment (creatinine clearance &lt; 50 mL/min) (see section 4.4).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Based on experience with oral paliperidone, no dose adjustment is required in patients with mild or moderate hepatic impairment. As paliperidone has not been studied in patients with severe hepatic impairment, caution is recommended in such patients (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Invega Sustenna in children and adolescents &lt; 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Invega Sustenna is intended for intramuscular use only. It must not be administered by any other route. It should be injected slowly, deep into the deltoid or gluteal muscle. Each injection should be administered by a healthcare professional. Administration should be in a single injection. The dose should not be given in divided injections.</p><p>&nbsp;</p><p>The day 1 and day 8 initiation doses must each be administered in the deltoid muscle in order to attain therapeutic concentrations rapidly (see section 5.2). Following the second initiation dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. A switch from gluteal to deltoid (and <em>vice versa</em>) should be considered in the event of injection site pain if the injection site discomfort is not well tolerated (see section 4.8). It is also recommended to alternate between left and right sides (see below).</p><p>&nbsp;</p><p>For instructions for use and handling of Invega Sustenna, see package leaflet (information intended for medical or healthcare professionals).</p><p>&nbsp;</p><p><em>Deltoid muscle administration</em></p><p>The recommended needle size for initial and maintenance administration of Invega Sustenna into the deltoid muscle is determined by the patient&rsquo;s weight. For those &ge; 90 kg, the 1&frac12; inch, 22 gauge needle (38.1 mm x 0.72 mm) is recommended. For those &lt; 90 kg, the 1-inch, 23 gauge needle (25.4 mm x</p><p>0.64 mm) is recommended. Deltoid injections should be alternated between the two deltoid muscles.</p><p>&nbsp;</p><p><em>Gluteal muscle administration</em></p><p>The recommended needle size for maintenance administration of Invega Sustenna into the gluteal muscle is the 1&frac12;-inch, 22 gauge needle (38.1 mm x 0.72 mm). Administration should be made into the</p><p>&nbsp;</p><p>upper-outer quadrant of the gluteal area. Gluteal injections should be alternated between the two gluteal muscles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance, to risperidone or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use in patients who are in an acutely agitated or severely psychotic state</u></p><p>&nbsp;</p><p>Invega Sustenna should not be used to manage acutely agitated or severely psychotic states when immediate symptom control is warranted.</p><p>&nbsp;</p><p><u>QT interval</u></p><p>&nbsp;</p><p>Caution should be exercised when paliperidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, and in concomitant use with other medicinal products thought to prolong the QT interval.</p><p>&nbsp;</p><p><u>Neuroleptic malignant syndrome</u></p><p>&nbsp;</p><p>Neuroleptic Malignant Syndrome (NMS), characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness, and elevated serum creatine phosphokinase levels has been reported to occur with paliperidone. Additional clinical signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. If a patient develops signs or symptoms indicative of NMS, paliperidone should be discontinued.</p><p>&nbsp;</p><p><u>Tardive dyskinesia/extrapyramidal symptoms</u></p><p>&nbsp;</p><p>Medicinal products with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical, involuntary movements, predominantly of the tongue and/or face. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics, including paliperidone, should be considered.</p><p>&nbsp;</p><p>Caution is warranted in patients receiving both, psychostimulants (e.g., methylphenidate) and paliperidone concomitantly, as extrapyramidal symptoms could emerge when adjusting one or both medications. Gradual withdrawal of stimulant treatment is recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Leucopenia, neutropenia, and agranulocytosis</u></p><p>&nbsp;</p><p>Events of leucopenia, neutropenia, and agranulocytosis have been reported with Invega Sustenna. Agranulocytosis has been reported very rarely (&lt; 1/10,000 patients) during post-marketing surveillance. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of Invega Sustenna should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt; 1 x 10<sup>9</sup>/L) should discontinue Invega Sustenna and have their WBC followed until recovery.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>&nbsp;</p><p>Anaphylactic reactions in patients who have previously tolerated oral risperidone or oral paliperidone have been rarely reported during post-marketing experience (see sections 4.1 and 4.8).</p><p>&nbsp;</p><p>If hypersensitivity reactions occur, discontinue use of Invega Sustenna; initiate general supportive measures as clinically appropriate and monitor the patient until signs and symptoms resolve (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>&nbsp;</p><p>Hyperglycaemia, diabetes mellitus, and exacerbation of pre-existing diabetes including diabetic coma and ketoacidosis, have been reported during treatment with paliperidone. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines. Patients treated with Invega Sustenna should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.</p><p>&nbsp;</p><p><u>Weight gain</u></p><p>&nbsp;</p><p>Significant weight gain has been reported with Invega Sustenna use. Weight should be monitored regularly.</p><p>&nbsp;</p><p><u>Use in patients with prolactin-dependent tumours</u></p><p>&nbsp;</p><p>Tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Although no clear association with the administration of antipsychotics has so far been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history. Paliperidone should be used with caution in patients with a pre-existing tumour that may be prolactin-dependent.</p><p>&nbsp;</p><p><u>Orthostatic hypotension</u></p><p>&nbsp;</p><p>Paliperidone may induce orthostatic hypotension in some patients based on its alpha-blocking activity. Based on pooled data from the three placebo-controlled, 6-week, fixed-dose trials with oral paliperidone prolonged release tablets (3, 6, 9, and 12 mg), orthostatic hypotension was reported by 2.5% of subjects treated with oral paliperidone compared with 0.8% of subjects treated with placebo. Invega Sustenna should be used with caution in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction or ischaemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g. dehydration and hypovolaemia).</p><p>&nbsp;</p><p><u>Seizures</u></p><p>&nbsp;</p><p>Invega Sustenna should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>The plasma concentrations of paliperidone are increased in patients with renal impairment and therefore, dose adjustment is recommended in patients with mild renal impairment. Invega Sustenna is not recommended in patients with moderate or severe renal impairment (creatinine clearance</p><p>&lt; 50 mL/min) (see sections 4.2 and 5.2). <u>Hepatic impairment</u></p><p>No data are available in patients with severe hepatic impairment (Child-Pugh class C). Caution is recommended if paliperidone is used in such patients.</p><p>&nbsp;</p><p><u>Elderly patients with dementia</u></p><p>&nbsp;</p><p>Invega Sustenna has not been studied in elderly patients with dementia. Invega Sustenna should be used with caution in elderly patients with dementia with risk factors for stroke.</p><p>&nbsp;</p><p>The experience from risperidone cited below is considered valid also for paliperidone.</p><p>&nbsp;</p><p><em>Overall mortality</em></p><p>In a meta-analysis of 17 controlled clinical trials, elderly patients with dementia treated with other atypical antipsychotics, including risperidone, aripiprazole, olanzapine, and quetiapine had an increased risk of mortality compared to placebo. Among those treated with risperidone, the mortality was 4% compared with 3.1% for placebo.</p><p>&nbsp;</p><p><em>Cerebrovascular adverse reactions</em></p><p>An approximately 3-fold increased risk of cerebrovascular adverse reactions has been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics, including risperidone, aripiprazole, and olanzapine. The mechanism for this increased risk is not known.</p><p>&nbsp;</p><p><u>Parkinson&rsquo;s disease and dementia with Lewy bodies</u></p><p>&nbsp;</p><p>Physicians should weigh the risks versus the benefits when prescribing Invega Sustenna to patients with Parkinson&rsquo;s Disease or Dementia with Lewy Bodies (DLB) since both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotics. Manifestation of this increased sensitivity can include confusion, obtundation, postural instability with frequent falls, in addition to extrapyramidal symptoms.</p><p>&nbsp;</p><p><u>Priapism</u></p><p>&nbsp;</p><p>Antipsychotic medicinal products (including risperidone) with alpha-adrenergic blocking effects have been reported to induce priapism. During post-marketing surveillance, priapism has also been reported with oral paliperidone, which is the active metabolite of risperidone. Patients should be informed to seek urgent medical care in case that priapism has not been resolved within 4 hours.</p><p>&nbsp;</p><p><u>Body temperature regulation</u></p><p>&nbsp;</p><p>Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotic medicinal products. Appropriate care is advised when prescribing Invega Sustenna to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medicinal products with anticholinergic activity or being subject to dehydration.</p><p>&nbsp;</p><p><u>Venous thromboembolism</u></p><p>&nbsp;</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Invega Sustenna and preventative measures undertaken.</p><p>&nbsp;</p><p><u>Antiemetic effect</u></p><p>&nbsp;</p><p>An antiemetic effect was observed in preclinical studies with paliperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicinal products or of conditions such as intestinal obstruction, Reye&rsquo;s syndrome and brain tumour.</p><p>&nbsp;</p><p><u>Administration</u></p><p>&nbsp;</p><p>Care must be taken to avoid inadvertent injection of Invega Sustenna into a blood vessel.</p><p>&nbsp;</p><p><u>Intraoperative Floppy Iris Syndrome</u></p><p>&nbsp;</p><p>Intraoperative floppy iris syndrome (IFIS) has been observed during cataract surgery in patients treated with medicinal products with alpha 1a-adrenergic antagonist effect, such as Invega Sustenna (see section 4.8).</p><p>&nbsp;</p><p>IFIS may increase the risk of eye complications during and after the operation. Current or past use of medicinal products with alpha 1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery. The potential benefit of stopping alpha 1 blocking therapy prior to cataract surgery has not been established and must be weighed against the risk of stopping the antipsychotic therapy.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially sodium-free.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution is advised when prescribing Invega Sustenna with medicinal products known to prolong the QT interval, e.g. class IA antiarrhythmics (e.g., quinidine, disopyramide) and class III antiarrhythmics (e.g. amiodarone, sotalol), some antihistaminics, some other antipsychotics and some antimalarials (e.g. mefloquine). This list is indicative and not exhaustive.</p><p>&nbsp;</p><p><u>Potential for Invega Sustenna to affect other medicines</u></p><p>&nbsp;</p><p>Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicinal products that are metabolised by cytochrome P-450 isozymes.</p><p>&nbsp;</p><p>Given the primary central nervous system (CNS) effects of paliperidone (see section 4.8), Invega Sustenna should be used with caution in combination with other centrally acting medicinal products, e.g., anxiolytics, most antipsychotics, hypnotics, opiates, etc. or alcohol.</p><p>&nbsp;</p><p>Paliperidone may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed necessary, particularly in end-stage Parkinson&rsquo;s disease, the lowest effective dose of each treatment should be prescribed.</p><p>&nbsp;</p><p>Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be observed when Invega Sustenna is administered with other therapeutic agents that have this potential, e.g., other antipsychotics, tricyclics.</p><p>&nbsp;</p><p>Caution is advised if paliperidone is combined with other medicinal products known to lower the seizure threshold (i.e., phenothiazines or butyrophenones, tricyclics or SSRIs, tramadol, mefloquine, etc.).</p><p>&nbsp;</p><p>Co-administration of oral paliperidone prolonged release tablets at steady-state (12 mg once daily) with divalproex sodium prolonged release tablets (500 mg to 2,000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.</p><p>&nbsp;</p><p>No interaction study between Invega Sustenna and lithium has been performed, however, a pharmacokinetic interaction is not likely to occur.</p><p>&nbsp;</p><p><u>Potential for other medicines to affect Invega Sustenna</u></p><p>&nbsp;</p><p><em>In vitro </em>studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, but there are no indications <em>in vitro </em>nor <em>in vivo </em>that these isozymes play a significant role in the metabolism of paliperidone. Concomitant administration of oral paliperidone with paroxetine, a</p><p>&nbsp;</p><p>potent CYP2D6 inhibitor, showed no clinically significant effect on the pharmacokinetics of paliperidone.</p><p>&nbsp;</p><p>Co-administration of oral paliperidone prolonged release once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone likely as a result of induction of renal P-gp by carbamazepine. A minor decrease in the amount of active substance excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. Larger decreases in plasma concentrations of paliperidone could occur with higher doses of carbamazepine.</p><p>On initiation of carbamazepine, the dose of Invega Sustenna should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of Invega Sustenna should be re-evaluated and decreased if necessary.</p><p>&nbsp;</p><p>Co-administration of a single dose of an oral paliperidone prolonged release tablet 12 mg with divalproex sodium prolonged release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone, likely as a result of increased oral absorption. Since no effect on the systemic clearance was observed, a clinically significant interaction would not be expected between divalproex sodium prolonged release tablets and Invega Sustenna intramuscular injection. This interaction has not been studied with Invega Sustenna.</p><p>&nbsp;</p><p><u>Concomitant use of Invega Sustenna with risperidone or with oral paliperidone</u></p><p>&nbsp;</p><p>Since paliperidone is the major active metabolite of risperidone, caution should be exercised when Invega Sustenna is co-administered with risperidone or with oral paliperidone for extended periods of time. Safety data involving concomitant use of Invega Sustenna with other antipsychotics is limited.</p><p>&nbsp;</p><p><u>Concomitant use of Invega Sustenna with psychostimulants</u></p><p>&nbsp;</p><p>The combined use of psychostimulants (e.g., methylphenidate) with paliperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of paliperidone during pregnancy. Intramuscularly injected paliperidone palmitate and orally administered paliperidone were not teratogenic in animal studies, but other types of reproductive toxicity were seen (see section 5.3). Neonates exposed to paliperidone during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully. Invega Sustenna should not be used during pregnancy unless clearly necessary.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Paliperidone is excreted in the breast milk to such an extent that effects on the breast-fed infant are likely if therapeutic doses are administered to breast-feeding women. Invega Sustenna should not be used while breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There were no relevant effects observed in the non-clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paliperidone can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred (see section 4.8). Therefore, patients should be advised not to drive or operate machines until their individual susceptibility to Invega Sustenna is known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Summary of the safety profile<br />The adverse&nbsp;reactions most frequently<br />reported in clinical trials were insomnia, headache,<br />anxiety, upper respiratory tract infection, injection<br />site reaction, parkinsonism, weight increased,<br />akathisia, agitation, sedation/somnolence, nausea,<br />constipation, dizziness, musculoskeletal pain,<br />tachycardia, tremor, abdominal pain, vomiting,<br />diarrhoea, fatigue, and dystonia. Of these, akathisia<br />and sedation/somnolence appeared to be<br />dose-related.<br />Tabulated list of adverse reactions<br />The following are all adverse reactions that<br />were reported with paliperidone by frequency<br />category estimated from paliperidone palmitate<br />clinical trials. The following terms and frequencies<br />are applied: very common (&ge; 1/10); common<br />(&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1, 000 to<br />&lt; 1/100); rare (&ge; 1/10, 000 to &lt; 1/1, 000); very rare<br />(&lt; 1/10, 000); and not known (cannot be estimated<br />from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:642px"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse&nbsp;Reactions</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>upper respiratory tract infection, urinary tract infection, influenza</p></td><td style="vertical-align:top"><p>pneumonia, bronchitis, respiratory tract infection, sinusitis, cystitis, ear infection, tonsillitis, onychomycosis,</p><p>cellulitis, subcutaneous abcess</p></td><td style="vertical-align:top"><p>eye infection, acarodermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>white blood cell count decreased,</p><p>anaemia</p></td><td style="vertical-align:top"><p>neutropenia, thrombocytopenia,&nbsp;eosinophil count increased</p></td><td style="vertical-align:top"><p>agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperprolactinaemia<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>inappropriate antidiuretic hormone</p><p>secretion, glucose urine present</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperglycaemia, weight increased, weight decreased, decreased appetite</p></td><td style="vertical-align:top"><p>diabetes mellitus<sup>d</sup>, hyperinsulinaemia, increased appetite, anorexia, blood triglycerides increased,</p><p>blood cholesterol increased</p></td><td style="vertical-align:top"><p>diabetic ketoacidosis, hypoglycaemia, polydipsia</p></td><td style="vertical-align:top"><p>water intoxication</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>insomnia<sup>e</sup></p></td><td style="vertical-align:top"><p>agitation, depression, anxiety</p></td><td style="vertical-align:top"><p>sleep disorder, mania, libido decreased, nervousness, nightmare</p></td><td style="vertical-align:top"><p>catatonia, confusional state, somnambulism,</p><p>blunted affect, anorgasmia</p></td><td style="vertical-align:top"><p>sleep-related eating disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>parkinsonismc, akathisiac, sedation/somnolence, dystoniac, dizziness, dyskinesiac, tremor, headache</p></td><td style="vertical-align:top"><p>tardive dyskinesia, syncope, psychomotor hyperactivity, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paraesthesia</p></td><td style="vertical-align:top"><p>neuroleptic malignant syndrome, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of consciousness, convulsione, balance disorder,</p><p>coordination abnormal, head titubation</p></td><td style="vertical-align:top"><p>diabetic coma</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vision blurred, conjunctivitis, dry eye</p></td><td style="vertical-align:top"><p>glaucoma, eye movement disorder, eye rolling, photophobia, lacrimation</p><p>increased, ocular hyperaemia</p></td><td style="vertical-align:top"><p>floppy iris syndrome (intraoperative)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vertigo, tinnitus, ear pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tachycardia</p></td><td style="vertical-align:top"><p>atrioventricular block, conduction disorder, electrocardiogram QT prolonged, postural orthostatic tachycardia syndrome, bradycardia,</p><p>electrocardiogram abnormal, palpitations</p></td><td style="vertical-align:top"><p>atrial fibrillation, sinus arrhythmia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>hypotension, orthostatic hypotension</p></td><td style="vertical-align:top"><p>pulmonary</p><p>embolism, venous</p><p>thrombosis, flushing</p></td><td style="vertical-align:top"><p>ischaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cough, nasal congestion</p></td><td style="vertical-align:top"><p>dyspnoea,</p><p>pharyngolaryngeal pain, epistaxis</p></td><td style="vertical-align:top"><p>sleep apnoea syndrome, pulmonary congestion, rales,&nbsp;wheezing</p></td><td style="vertical-align:top"><p>hyperventilation, pneumonia aspiration, dysphonia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain, vomiting, nausea, constipation, diarrhoea, dyspepsia, toothache</p></td><td style="vertical-align:top"><p>abdominal discomfort, gastroenteritis, dysphagia, dry mouth, flatulence</p></td><td style="vertical-align:top"><p>pancreatitis,&nbsp;intestinal obstruction, swollen tongue, faecal incontinence,</p><p>faecaloma, cheilitis</p></td><td style="vertical-align:top"><p>ileus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>transaminases increased</p></td><td style="vertical-align:top"><p>gamma- glutamyltransferase</p><p>increased, hepatic enzyme increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>jaundice</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>urticaria, pruritus, rash, alopecia, eczema, dry skin, erythema, acne</p></td><td style="vertical-align:top"><p>drug eruption, hyperkeratosis, seborrhoeic dermatitis, dandruff</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome/toxic epidermal necrolysis, angioedema, skin discolouration</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>musculoskeletal pain, back pain, arthralgia</p></td><td style="vertical-align:top"><p>blood creatine phosphokinase increased, muscle spasms, joint stiffness,</p><p>muscular weakness</p></td><td style="vertical-align:top"><p>rhabdomyolysis, joint swelling</p></td><td style="vertical-align:top"><p>posture abnormal</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and</strong></p><p><strong>urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>urinary incontinence, pollakiuria, dysuria</p></td><td style="vertical-align:top"><p>urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium and</strong></p><p><strong>perinatal conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>amenorrhoea</p></td><td style="vertical-align:top"><p>erectile dysfunction, ejaculation disorder, menstrual disordere, gynaecomastia, galactorrhoea, sexual</p><p>dysfunction, breast pain</p></td><td style="vertical-align:top"><p>priapism, breast discomfort, breast engorgement, breast</p><p>enlargement, vaginal discharge</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pyrexia, asthenia, fatigue, injection site reaction</p></td><td style="vertical-align:top"><p>face oedema, oedemae,</p><p>body temperature increased, gait abnormal, chest pain, chest discomfort, malaise, induration</p></td><td style="vertical-align:top"><p>hypothermia, chills, thirst, drug withdrawal syndrome, injection site abscess, injection site cellulitis, injection site cyst,</p><p>injection site haematoma</p></td><td style="vertical-align:top"><p>body temperature decreased, injection site necrosis, injection site ulcer</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural</strong></p><p><strong>complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fall</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The frequency of adverse reactions is qualified as &ldquo;not known&rdquo; because they were not observed in paliperidone</p><p>palmitate clinical trials. They were either derived from spontaneous post-marketing reports and frequency cannot be determined, or they were derived from risperidone (any formulation) or oral paliperidone clinical trials data and/or post-marketing reports.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refer to &lsquo;Hyperprolactinaemia&rsquo; below.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refer to &lsquo;Extrapyramidal symptoms&rsquo; below.</p><p>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In placebo-controlled trials, diabetes mellitus was reported in 0.32% in Invega Sustenna-treated subjects compared to a rate of 0.39% in placebo group. Overall incidence from all clinical trials was 0.65% in all Invega Sustenna-treated subjects.</p><p>e&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Insomnia includes: </strong>initial insomnia, middle insomnia; <strong>Convulsion includes: </strong>grand mal convulsion; Oedema includes:</p><p>generalised oedema, oedema peripheral, pitting oedema. <strong>Menstrual disorder includes: </strong>menstruation delayed, menstruation irregular, oligomenorrhoea.</p><p>&nbsp;</p><p><u>Undesirable effects noted with risperidone formulations</u></p><p>&nbsp;</p><p>Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Anaphylactic reaction</em></p><p>Rarely, cases of anaphylactic reaction after injection with Invega Sustenna have been reported during post-marketing experience in patients who have previously tolerated oral risperidone or oral paliperidone (see section 4.4).</p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>The most commonly reported injection site related adverse reaction was pain. The majority of these reactions were reported to be of mild to moderate severity. Subject evaluations of injection site pain based on a visual analogue scale tended to lessen in frequency and intensity over time in all Phase 2 and 3 studies with Invega Sustenna. Injections into the deltoid were perceived as slightly more painful than corresponding gluteal injections. Other injection site reactions were mostly mild in intensity and included induration (common), pruritus (uncommon) and nodules (rare).</p><p>&nbsp;</p><p><em>Extrapyramidal symptoms (EPS)</em></p><p>EPS included a pooled analysis of the following terms: parkinsonism (includes salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, glabellar reflex abnormal, and parkinsonian rest tremor), akathisia (includes akathisia, restlessness, hyperkinesia, and restless leg syndrome), dyskinesia (dyskinesia, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia (includes dystonia, hypertonia, torticollis, muscle</p><p>&nbsp;</p><p>contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus), and tremor. It should be noted that a broader spectrum of symptoms are included that do not necessarily have an extrapyramidal origin.</p><p>&nbsp;</p><p><em>Weight gain</em></p><p>In the 13-week study involving the 150 mg initiation dosing, the proportion of subjects with an abnormal weight increase &ge; 7% showed a dose-related trend, with a 5% incidence rate in the placebo group compared with rates of 6%, 8% and 13% in the Invega Sustenna 25 mg, 100 mg, and 150 mg groups, respectively.</p><p>&nbsp;</p><p>During the 33-week open-label transition/maintenance period of the long-term recurrence prevention trial, 12% of Invega Sustenna-treated subjects met this criterion (weight gain of &ge; 7% from</p><p>double-blind phase to endpoint); the mean (SD) weight change from open-label baseline was</p><p>+ 0.7 (4.79) kg.</p><p>&nbsp;</p><p><em>Hyperprolactinaemia</em></p><p>In clinical trials, median increases in serum prolactin were observed in subjects of both genders who received Invega Sustenna. Adverse reactions that may suggest increase in prolactin levels (e.g., amenorrhoea, galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in &lt; 1% of subjects.</p><p>&nbsp;</p><p><u>Class effects</u></p><p>&nbsp;</p><p>QT prolongation, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia), sudden unexplained death, cardiac arrest, and Torsade de pointes may occur with antipsychotics.</p><p>&nbsp;</p><p>Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotic medicinal products (frequency unknown).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medical product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>To Report any side effect (s):</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o&nbsp; SFDA call centre: 19999</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o Website: http://ade.sfda.gov.sa</p><p><strong>&bull;&nbsp; Other GCC states:</strong></p><p>&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>&nbsp;</p><p>In general, expected signs and symptoms are those resulting from an exaggeration of paliperidone&rsquo;s known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, QT</p><p>&nbsp;</p><p>prolongation, and extrapyramidal symptoms. Torsade de pointes and ventricular fibrillation have been reported in a patient in the setting of overdose with oral paliperidone. In the case of acute overdose, the possibility of multiple drug involvement should be considered.</p><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>Consideration should be given to the prolonged release nature of the medicinal product and the long elimination half-life of paliperidone when assessing treatment needs and recovery. There is no specific antidote to paliperidone. General supportive measures should be employed. Establish and maintain a clear airway and ensure adequate oxygenation and ventilation.</p><p>&nbsp;</p><p>Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring for possible arrhythmias. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluid and/or sympathomimetic agents. In case of severe extrapyramidal symptoms, anticholinergic agents should be administered. Close supervision and monitoring should continue until the patient recovers.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psycholeptics, other antipsychotics. ATC code: N05AX13 Invega Sustenna contains a racemic mixture of (+)- and (-)-paliperidone.</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Paliperidone is a selective blocking agent of monoamine effects, whose pharmacological properties are different from that of traditional neuroleptics. Paliperidone binds strongly to serotonergic 5-HT2- and dopaminergic D2-receptors. Paliperidone also blocks alpha 1-adrenergic receptors and slightly less, H1-histaminergic and alpha 2-adrenergic receptors. The pharmacological activity of the (+)- and (-)-paliperidone enantiomers are qualitatively and quantitatively similar.</p><p>&nbsp;</p><p>Paliperidone is not bound to cholinergic receptors. Even though paliperidone is a strong</p><p>D2-antagonist, which is believed to relieve the positive symptoms of schizophrenia, it causes less catalepsy and decreases motor functions less than traditional neuroleptics. Dominating central serotonin antagonism may reduce the tendency of paliperidone to cause extrapyramidal side effects.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p><em>Acute treatment of schizophrenia</em></p><p>The efficacy of Invega Sustenna in the acute treatment of schizophrenia was established in four</p><p>short-term (one 9-week and three 13-week) double-blind, randomised, placebo-controlled, fixed-dose studies of acutely relapsed adult inpatients who met DSM-IV criteria for schizophrenia. The fixed doses of Invega Sustenna in these studies were given on days 1, 8, and 36 in the 9-week study, and additionally on day 64 of the 13-week studies. No additional oral antipsychotic supplementation was needed during the acute treatment of schizophrenia with Invega Sustenna. The primary efficacy endpoint was defined as a decrease in Positive and Negative Syndrome Scale (PANSS) total scores as shown in the table below. The PANSS is a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganised thoughts, uncontrolled hostility/excitement and anxiety/depression. Functioning was evaluated using the Personal and Social Performance (PSP) scale. The PSP is a validated clinician rated scale that measures personal and social functioning in four domains: socially useful activities (work and study), personal and social relationships, self-care and disturbing and aggressive behaviours.</p><p>&nbsp;</p><p>In a 13-week study (n = 636) comparing three fixed doses of Invega Sustenna (initial deltoid injection of 150 mg followed by 3 gluteal or deltoid doses of either 25 mg/4 weeks, 100 mg/4 weeks or</p><p>150 mg/4 weeks) to placebo, all three doses of Invega Sustenna were superior to placebo in improving the PANSS total score. In this study, both the 100 mg/4 weeks and 150 mg /4 weeks, but not the</p><p>25 mg/4 weeks, treatment groups demonstrated statistical superiority to placebo for the PSP score. These results support efficacy across the entire duration of treatment and improvement in PANSS and was observed as early as day 4 with significant separation from placebo in the 25 mg and 150 mg Invega Sustenna groups by day 8.</p><p>&nbsp;</p><p>The results of the other studies yielded statistically significant results in favour of Invega Sustenna, except for the 50 mg dose in one study (see table below).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score - Change From Baseline to End Point- LOCF for Studies R092670-SCH-201, R092670-PSY-3003, R092670-PSY-3004 and</p><p>R092670-PSY-3007: Primary Efficacy Analysis Set</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>25 mg</p></td><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>150 mg</p></td></tr><tr><td style="vertical-align:top"><p><strong>R092670-PSY-3007</strong>*</p></td><td style="vertical-align:top"><p>n = 160</p></td><td style="vertical-align:top"><p>n = 155</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n = 161</p></td><td style="vertical-align:top"><p>n = 160</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline (SD)</p></td><td style="vertical-align:top"><p>86.8 (10.31)</p></td><td style="vertical-align:top"><p>86.9 (11.99)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>86.2 (10.77)</p></td><td style="vertical-align:top"><p>88.4 (11.70)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change (SD)</p></td><td style="vertical-align:top"><p>-2.9 (19.26)</p></td><td style="vertical-align:top"><p>-8.0 (19.90)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>-11.6 (17.63)</p></td><td style="vertical-align:top"><p>-13.2 (18.48)</p></td></tr><tr><td style="vertical-align:top"><p>P-value (vs. Placebo)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>R092670-PSY-3003</strong></p></td><td style="vertical-align:top"><p>n = 132</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n = 93</p></td><td style="vertical-align:top"><p>n = 94</p></td><td style="vertical-align:top"><p>n = 30</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline (SD)</p></td><td style="vertical-align:top"><p>92.4 (12.55)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>89.9 (10.78)</p></td><td style="vertical-align:top"><p>90.1 (11.66)</p></td><td style="vertical-align:top"><p>92.2 (11.72)</p></td></tr><tr><td style="vertical-align:top"><p>Mean change (SD)</p></td><td style="vertical-align:top"><p>-4.1 (21.01)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>-7.9 (18.71)</p></td><td style="vertical-align:top"><p>-11.0 (19.06)</p></td><td style="vertical-align:top"><p>-5.5 (19.78)</p></td></tr><tr><td style="vertical-align:top"><p>P-value (vs. Placebo)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.193</p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p><strong>R092670-PSY-3004</strong></p></td><td style="vertical-align:top"><p>n = 125</p></td><td style="vertical-align:top"><p>n = 129</p></td><td style="vertical-align:top"><p>n = 128</p></td><td style="vertical-align:top"><p>n = 131</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline (SD)</p></td><td style="vertical-align:top"><p>90.7 (12.22)</p></td><td style="vertical-align:top"><p>90.7 (12.25)</p></td><td style="vertical-align:top"><p>91.2 (12.02)</p></td><td style="vertical-align:top"><p>90.8 (11.70)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean change (SD)</p></td><td style="vertical-align:top"><p>-7.0 (20.07)</p></td><td style="vertical-align:top"><p>-13.6 (21.45)</p></td><td style="vertical-align:top"><p>-13.2 (20.14)</p></td><td style="vertical-align:top"><p>-16.1 (20.36)</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>P-value (vs. Placebo)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>R092670-SCH-201</strong></p></td><td style="vertical-align:top"><p>n = 66</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n = 63</p></td><td style="vertical-align:top"><p>n = 68</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean baseline (SD)</p></td><td style="vertical-align:top"><p>87.8 (13.90)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>88.0 (12.39)</p></td><td style="vertical-align:top"><p>85.2 (11.09)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean change (SD)</p></td><td style="vertical-align:top"><p>6.2 (18.25)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>-5.2 (21.52)</p></td><td style="vertical-align:top"><p>-7.8 (19.40)</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>P-value (vs. Placebo)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.001</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* For Study R092670-PSY-3007 an initiation dose of 150 mg was given to all subjects in the Invega Sustenna treatment groups on day 1 followed by the assigned dose afterwards.</p><p>Note: Negative change in score indicates improvement.</p><p>&nbsp;</p><p><em>Maintaining symptom control and delaying relapse of schizophrenia</em></p><p>The efficacy of Invega Sustenna in maintaining symptomatic control and delaying relapse of schizophrenia was established in a longer-term double-blind, placebo-controlled, flexible-dose study involving 849 non-elderly adult subjects who met DSM-IV criteria for schizophrenia. This study included a 33-week open-label acute treatment and stabilisation phase, a randomised, double-blind placebo-controlled phase to observe for relapse, and a 52-week open-label extension period. In this study, doses of Invega Sustenna included 25, 50, 75, and 100 mg administered monthly; the 75 mg dose was allowed only in the 52-week open-label extension. Subjects initially received flexible doses (25-100 mg) of Invega Sustenna during a 9-week transition period, followed by a 24-week maintenance period, where subjects were required to have a PANSS score of &le; 75. Dosing adjustments were only allowed in the first 12 weeks of the maintenance period. A total of 410 stabilised patients were randomised to either Invega Sustenna (median duration 171 days [range 1 day to 407 days]) or to placebo (median duration 105 days [range 8 days to 441 days]) until they experienced a relapse of schizophrenia symptoms in the variable length double-blind phase. The trial was stopped early for efficacy reasons as a significantly longer time to relapse (p &lt; 0.0001, Figure 1) was seen in patients treated with Invega Sustenna compared to placebo (hazard ratio = 4.32; 95% CI: 2.4-7.7).</p><p>&nbsp;</p><p><img alt="" width="762" height="573" src="data:image/jpeg;base64,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" /></p><p><strong>Figure 1:&nbsp;&nbsp;&nbsp; </strong>Kaplan-Meier Plot of Time to Relapse &ndash; Interim Analysis (Intent-to-Treat Interim Analysis Set)</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Invega Sustenna in all subsets of the paediatric population in schizophrenia. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p>&nbsp;</p><p>Paliperidone palmitate is the palmitate ester prodrug of paliperidone. Due to its extremely low water solubility, paliperidone palmitate dissolves slowly after intramuscular injection before being hydrolysed to paliperidone and absorbed into the systemic circulation. Following a single intramuscular dose, the plasma concentrations of paliperidone gradually rise to reach maximum plasma concentrations at a median Tmax of 13 days. The release of the active substance starts as early as day 1 and lasts for at least 4 months.</p><p>&nbsp;</p><p>Following intramuscular injection of single doses (25-150 mg) in the deltoid muscle, on average, a 28% higher Cmax was observed compared with injection in the gluteal muscle. The two initial deltoid intramuscular injections of 150 mg on day 1 and 100 mg on day 8 help attain therapeutic concentrations rapidly. The release profile and dosing regimen of Invega Sustenna results in sustained therapeutic concentrations. The total exposure of paliperidone following Invega Sustenna administration was dose-proportional over a 25-150 mg dose range, and less than dose-proportional for Cmax for doses exceeding 50 mg. The mean steady-state peak:trough ratio for a Invega Sustenna dose of 100 mg was 1.8 following gluteal administration and 2.2 following deltoid administration. The</p><p>&nbsp;</p><p>median apparent half-life of paliperidone following Invega Sustenna administration over the dose range of 25-150 mg ranged from 25-49 days.</p><p>&nbsp;</p><p>The absolute bioavailability of paliperidone palmitate following Invega Sustenna administration is 100%.</p><p>&nbsp;</p><p>Following administration of paliperidone palmitate the (+) and (-) enantiomers of paliperidone interconvert, reaching an AUC (+) to (-) ratio of approximately 1.6-1.8.</p><p>&nbsp;</p><p>The plasma protein binding of racemic paliperidone is 74%.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>One week following administration of a single oral dose of 1 mg immediate-release <sup>14</sup>C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised in the liver. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the faeces. Four metabolic pathways have been identified <em>in vivo</em>, none of which accounted for more than 6.5% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Although <em>in vitro </em>studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, there is no evidence <em>in vivo </em>that these isozymes play a significant role in the metabolism of paliperidone. Population pharmacokinetics analyses indicated no discernible difference on the apparent clearance of paliperidone after administration of oral paliperidone between extensive metabolisers and poor metabolisers of CYP2D6 substrates. <em>In vitro </em>studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of medicinal products metabolised by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5.</p><p>&nbsp;</p><p><em>In vitro </em>studies have shown that paliperidone is a P-gp substrate and a weak inhibitor of P-gp at high concentrations. No <em>in vivo </em>data are available and the clinical relevance is unknown.</p><p>&nbsp;</p><p><u>Long acting paliperidone palmitate injection versus oral prolonged release paliperidone</u></p><p>&nbsp;</p><p>Invega Sustenna is designed to deliver paliperidone over a monthly period while prolonged release oral paliperidone is administered on a daily basis. The initiation regimen for Invega Sustenna</p><p>(150 mg/100 mg in the deltoid muscle on day 1/day 8) was designed to rapidly attain steady-state paliperidone concentrations when initiating therapy without the use of oral supplementation.</p><p>&nbsp;</p><p>In general, overall initiation plasma levels with Invega Sustenna were within the exposure range observed with 6-12 mg prolonged release oral paliperidone. The use of the Invega Sustenna initiation regimen allowed patients to stay in this exposure window of 6-12 mg prolonged release oral paliperidone even on trough pre-dose days (day 8 and day 36). Because of the difference in median pharmacokinetic profiles between the two medicinal products, caution should be exercised when making a direct comparison of their pharmacokinetic properties.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Paliperidone is not extensively metabolised in the liver. Although Invega Sustenna was not studied on patients with hepatic impairment, no dose adjustment is required in patients with mild or moderate hepatic impairment. In a study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects. Paliperidone has not been studied in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>The disposition of a single oral dose paliperidone 3 mg prolonged release tablet was studied in subjects with varying degrees of renal function. Elimination of paliperidone decreased with decreasing estimated creatinine clearance. Total clearance of paliperidone was reduced in subjects with impaired</p><p>&nbsp;</p><p>renal function by 32% on average in mild (CrCl = 50 to &lt; 80 mL/min), 64% in moderate (CrCl = 30 to</p><p>&lt; 50 mL/min), and 71% in severe (CrCl = 10 to &lt; 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUCinf) of 1.5, 2.6, and 4.8 fold, respectively, compared to healthy subjects. Based on a limited number of observations with Invega Sustenna in subjects with mild renal impairment and pharmacokinetic simulations, a reduced dose is recommended (see section 4.2).</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>Population pharmacokinetics analysis showed no evidence of age related pharmacokinetics differences.</p><p>&nbsp;</p><p><u>Body mass index (BMI)/body weight</u></p><p>&nbsp;</p><p>Pharmacokinetic studies with paliperidone palmitate have shown somewhat lower (10-20%) plasma concentrations of paliperidone in patients who are overweight or obese in comparison with normal weight patients (see section 4.2).</p><p>&nbsp;</p><p><u>Race</u></p><p>&nbsp;</p><p>Population pharmacokinetics analysis of data from studies with oral paliperidone revealed no evidence of race-related differences in the pharmacokinetics of paliperidone following Invega Sustenna administration.</p><p>&nbsp;</p><p><u>Gender</u></p><p>&nbsp;</p><p>No clinically significant differences were observed between men and women.</p><p>&nbsp;</p><p><u>Smoking status</u></p><p>Based on <em>in vitro </em>studies utilising human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone. Effect of smoking on the pharmacokinetics of paliperidone was not studied with Invega Sustenna. A population pharmacokinetic analysis based on data with oral paliperidone prolonged release tablets showed a slightly lower exposure to paliperidone in smokers compared with non-smokers. The difference is unlikely to be of clinical relevance.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeat-dose toxicity studies of intramuscularly injected paliperidone palmitate (the 1-month formulation) and orally administered paliperidone in rat and dog showed mainly pharmacological effects, such as sedation and prolactin-mediated effects on mammary glands and genitals. In animals treated with paliperidone palmitate an inflammatory reaction was seen at the intramuscular injection site. Occasionally abscess formation occurred.</p><p>&nbsp;</p><p>In rat reproduction studies with oral risperidone, which is extensively converted to paliperidone in rats and humans, adverse effects were seen on the birth weight and survival of the offspring. No embryotoxicity or malformations were observed following intramuscular administration of paliperidone palmitate to pregnant rats up to the highest dose (160 mg/kg/day) corresponding to</p><p>4.1 times the exposure level in humans at the maximum recommended dose of 150 mg. Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring.</p><p>&nbsp;</p><p>Paliperidone palmitate and paliperidone were not genotoxic. In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. The carcinogenic potential of intramuscularly injected paliperidone palmitate was assessed in rats. There was a statistically significant increase in mammary gland adenocarcinomas in female rats at 10, 30 and 60 mg/kg/month.</p><p>&nbsp;</p><p>Male rats showed a statistically significant increase in mammary gland adenomas and carcinomas at 30 and 60 mg/kg/month which is 1.2 and 2.2 times the exposure level at the maximum recommended human 150 mg dose. These tumours can be related to prolonged dopamine D2 antagonism and hyperprolactinaemia. The relevance of these tumour findings in rodents in terms of human risk is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polysorbate 20</p><p>Polyethylene glycol 4000</p><p>Citric acid monohydrate</p><p>Disodium hydrogen phosphate anhydrous</p><p>Sodium dihydrogen phosphate monohydrate</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>25 mg0.25 mL suspension in a pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, backstop, and tip cap (bromobutyl rubber) with a 22G 1&frac12;-inch safety needle (0.72 mm x 38.1 mm) and a 23G 1-inch safety needle (0.64 mm x 25.4 mm).</p><p><br />50 mg 0.5 mL suspension in a pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, backstop, and tip cap (bromobutyl rubber) with a 22G 1&frac12;-inch safety needle (0.72 mm x 38.1 mm) and a 23G 1-inch safety needle (0.64 mm x 25.4 mm).</p><p><br />75 mg 0.75 mL suspension in a pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, backstop, and tip cap (bromobutyl rubber) with a 22G 1&frac12;-inch safety needle (0.72 mm x 38.1 mm) and a 23G 1-inch safety needle (0.64 mm x 25.4 mm).</p><p><br />100 mg 1 mL suspension in a pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, backstop, and tip cap (bromobutyl rubber) with a 22G 1&frac12;-inch safety needle (0.72 mm x 38.1 mm) and a 23G 1-inch safety needle (0.64 mm x 25.4 mm).</p><p>150 mg 1.5 mL suspension in a pre-filled syringe (cyclic-olefin-copolymer) with a plunger stopper, backstop, and tip cap (bromobutyl rubber) with a 22G 1&frac12;-inch safety needle (0.72 mm x 38.1 mm) and a 23G 1-inch safety needle (0.64 mm x 25.4 mm).</p><p><br />Pack sizes:<br />Pack contains 1 pre-filled syringe and 2 needles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25-May-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>